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Abstract

PHYSICOCHEMICAL AND STRUCTURAL ANALYSIS OF POLYMERS AS
PUTATIVE DRUGS

By Meghan Lee Thompson, PhD

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2015

Director: Dr. Umesh Desai
Professor, Department of Medicinal Chemistry

Developing polymers as drugs is challenging work, but the therapeutic utility of
polymers is promising for the treatment of many disease states. Heparin, low molecular
weight heparins (LMWHs), and other glycosaminoglycans (GAGs) or GAG-like molecules
have therapeutic potential in clotting disorders, bladder pain, osteoarthritis, and tumor
metastasis.1,2,3 For LMWHs, the FDA uses five criteria to describe their similarities and
differences: source of UFH it is synthesized from, physicochemical characteristics,
xiv

structural composition, in vitro biological activity, and in vivo pharmacodynamics profile.4
Two of those criteria, the biological activity and pharmacodynamics, have been reported
for the promising polymers known as sulfated low molecular weight lignin (LMWLs),
originally developed as heparin mimetics.
Sulfated LMWLs have shown good activity as anticoagulants by allosterically
inhibiting thrombin, as well as promising agents for treating emphysema through inhibition
of elastolysis, oxidation, and inflammation5-9 Sulfated LMWLs are chemo-enzymatically
synthesized from starting monomers caffeic, ferulic, and sinapic acid into sulfated
dehydropolymers known as CDS, FDS, and SDS. In effort to fill in the gap of information
about the LMWLs and further their development as drugs, their structural composition
and physicochemical characteristics were defined in this work.
The molecular weight distribution profile of the sulfated LMWLs from size exclusion
chromatography performed on a high pressure liquid chromatography system (SECHPLC) changed from bimodal when no surfactant is used in the mobile phase of the HPLC
to unimodal when Tween 80 is used in the mobile phase. This indicates that some large
molecular weight species, likely an aggregate of smaller molecular weight chains, are
disrupted when surfactant is present. The resulting estimates of molecular weight
calculated when surfactant is used in the mobile phase resulted in peak average
molecular weights of 5700 Da for CDS, 7400 Da for FDS, and 4300 Da for SDS. These
molecular weights are 17-45% higher and can be considered more accurate than the
previously reported molecular weights (CDS: 3320 Da, FDS: 4120 Da, SDS: 3550 Da)
because they were measured directly whereas previous estimates were calculated from
SEC-HPLC data of the unsulfated LMWL precursors. Elemental analysis and
xv

octanol:water distribution coefficient measurements were also performed on the LMWL
library, revealing information about the level of sulfation and hydrophobic character of the
sulfated LMWLs.

xvi

1. Drug Development of Polymers
1.1 Polymers as drugs
The use of polymers in biomedicine has grown significantly in the last four decades
and the unique physiochemical properties of polymers have been exploited for a variety
of applications.10 Originally, polymers were recognized to be useful as carriers for site
specific and sustained delivery of therapeutic agents as polymer-drug conjugate
systems.10 However, polymers themselves can be intrinsically bioactive and researchers’
interest in developing polymers acting as active pharmaceutical ingredients is relatively a
more recent phenomenon.10 Polymers offer advantages over classic small molecule drug
candidates due to high molecular weight characteristics, even though these features do
not fit most “drug-likeness” definitions and violate “Lipinski’s Rules.”10 Benefits of
polymers as drugs include: lower toxicity, greater specificity, and polyvalency (enhanced
activity from multiple interactions with disease targets).10 Polymers may have lower
toxicity due to their high molecular weight characteristics that minimize absorption from
the site of action (such as the lung or the gut) and reduce off-target side effects. However,
some drug discovery and development scientists still consider polymeric drugs with
significant skepticism due to concerns with their broad molecular weight distribution
(polydispersity), poor oral bioavailability due to high molecular weight, stability in solution,
and compositional/ structural heterogeneity as shortcomings that impede development
and approval.10
Although developed polymeric drugs have only recently entered routine clinical
practice, natural polymers have been used in medicine for several millennia.11 In modern
times, the need for more careful identification of specific natural product macromolecular
1

drugs and more rigorous definition of the molecular basis of their mechanism of action is
paramount to developing approvable polymeric drugs. Divinylether-maleic anhydride
copolymer was one of the first biologically active polymeric drugs and was clinically tested
in the 1960s as an anticancer agent.10,11 Unfortunately, it failed clinical testing due to
severe toxicity related to subtle changes in polymer molecular weight and intravenous
route of administration.11 Development of therapeutic polymers and translation to the
clinic is therefore subject to many challenges, such as: industrial scale manufacture,
validated analytical techniques required to confirm identity and batch to batch
reproducibility of the often heterogeneous, hybrid macromolecular constructs, and
pharmaceutical formulations that ensure shelf-life stability and rapid solubilization of
particle-free solutions for safe injection.11 Drug development of heterogeneous,
polydisperse polymers requires complex structural and physicochemical characterization,
such as determination of molecular weight distributions (such as those described in this
work), to ensure equivalency of preparations.
1.2 Glycans
Glycans are saccharides and represent a wide array of structurally diverse
compounds that contain carbohydrate constituents and may be simple sugars
(monosaccharides) or polymeric oligosaccharides linked through inter-glycoside bonds.
Glycoscience, the study of these glycans and their interactions with biomacromolecules,
has historically received less focus and funding in comparison to protein or nucleic acid
science, leaving lots of room for growth and discovery. The National Research Council
Committee on Assessing the Importance and Impact of Glycomics and Glycosciences
has called for an increased focus on glycoscience in a 2012 report promising great

2

advances in the field.12 Rapid enhancements in our ability to understand and take
advantage of carbohydrate-protein interactions and new developments in glycoscience
techniques facilitate the success of research in this field.12,13
Glycans and proteins make up the matrix on the surface of all mammalian cells
known as the glycocalyx (Figure 1).14,15 The glycocalyx serves as the first site of contact
between cells as well as between cells and pathogens. Biological information encoded in
the glycans expressed in the glycocalyx is designated the glycocode, which can be
recognized specifically by lectins (carbohydrate binding proteins) to exert concrete
biological functions (e.g., cell signaling, molecular recognition, inflammation, and
immunity).15,16 Taking advantage of the functionality of protein-carbohydrate interactions
is therefore a promising area for drug development to target a myriad of disease states.

Figure 1. The glycocalyx that makes up the surface of all mammalian cells and contains
O-glycans, N-glycans, glycan binding proteins, and other glycans5

3

Glycans come in many forms linked to other biomolecules: glycolipids,
peptidoglycans, and glycoproteins. These glycoconjugates have a “glycone” portion
consisting of the glycan and an “aglycone” portion composed of the non-carbohydrate
part of the molecule. Glycolipids are lipids that have glycan chains attached such as
glycerolipids, sphingolipids, and gangliosides. Peptidoglycans form the bacterial cell wall
and consist of alternating polymer units of a N-acetylglucosamine and a N-acetylmuramic
acid that contains peptide chains. The majority of proteins are glycosylated, termed
glycoproteins, which are proteins that have been modified with glycan chains on
asparagine, serine, or threonine residues. Proteoglycans are a subclass of glycoproteins
that represent proteins which have been heavily glycosylated with glycosaminoglycan
(GAG) chains, such as decorin, sergylycin, perlecan, and aggrecan. Glycoproteins can
be divided into two general classes: N-linked (to asparagine) or O-linked (to seronine or
threonine).4N-glycans most commonly consist of N-acetylglucosamine residue covalently
bonded to asparagine. N-glycans are important physiologically for protein quality control
and aid in optimal folding of glycoproteins as chaperones. Pathologies involving N-glycans
include cystic fibrosis, liver cirrhosis, and cancer. Example structures of N- and O-linked
glycans are below (Figure 2).4,17
O-glycans consist of two major types: mucins and nonmucins. Mucins are typically
found in mucous secretions and as transmembrane glycoproteins with glycans exposed
to the external environment. Mucins are hydrophilic, negatively charged, contribute to
adhesion, and retain water and salt. There are many types of nonmucins that are
abundant in the cytoplasm and nucleus, though they were believed to be nonexistent just

4

a decade ago. O-glycans serve to regulate the activity of various transcription factors and
control the specificity and activity of transcription machinery.4

Figure 2. Example structures of typical N- and O-linked glycans9
1.3 Glycosaminoglycans
As mentioned above glycosaminoglycans (GAGs) are an important part of
proteoglycans and have considerable potential for therapeutic use due to their diverse
array of biological activities and potential disease targets. GAGs and GAG-like molecules
used as drugs may have lower toxicity due to their similarity in structure to endogenous
species in the body because all human cells are coated with glycans, making drugs that
are GAGs or conjugated with GAG-like polymers more biocompatible.

Despite

challenges discussed above that may potentially limit polymeric drug development,
several GAGs have achieved clinical approval and are in use as medicines today,
including anticoagulants: heparin, low molecular weight heparins, and fondaparinux, as
well as: hyaluronic acid (for osteoarthritis and wound healing) and chondroitin
sulfate/glucosamine (for osteoarthritis).4
5

Heparan sulfate is a GAG similar to heparin (both are biosynthesized as
copolymers of N-acetylglucosamine linked to either uronic acid or glatactose), but heparan
sulfate is made by virtually all cells in contrast to heparin which is made solely by
connective tissue-type mast cells (Figure 3). Heparan sulfate may contain anticoagulant
activity, but is typically much less active than heparin. 17 During biosynthesis, heparin
undergoes more extensive sulfation resulting in a sulfate to hexosamine ratio of 1.8-2.6
in comparison with 0.8-1.8 for heparan sulfate.17 Heparin also undergoes a greater
degree of uronic acid epimerization, with 80% or more of the N-acetylglucosamine
residues N-acetylated and N-sulfated, whereas only 40-60% epimerize in heparan sulfate.
Iduronic acid residues make up 30-50% of heparan sulfate, but more than 70% of heparin.

6

Heparan sulfate is also larger than heparin, with average molecular weight ranging from
10000 to 70000 Da.17

Figure 3. Classes of glycans, including the proteoglycans
glycosaminoglycans: heparan, chondroitin, and dermatan sulfate 9

modified

with

Chondroitin sulfate consists of repeating disaccharide units of sulfate substituted
N-acetylgalactosamine

and glucuronic acid polymerized into long chains (Figure 3).17

Peak average molecular weight of pharmaceutical grade chondroitin sulfate has been
determined to be about 20000 to 29000 Da.18 Glucosamine and chondroitin sulfate have
been promoted to relieve symptoms of osteoarthritis, a painful condition involving the age-

7

dependent erosion of articular cartilage. The primary glycans in cartilage, which provides
a cushion between bone joints to minimize mechanical damage, are hyaluronan and
chondroitin sulfate. A number of clinical trials have reported improvement of osteoarthritis
symptoms and a decreased rate of joint space narrowing following treatment with
chondroitin sulfate/glucosamine.17
Hyaluronan is the largest polysaccharide found in vertebrates and consists of ~104
repeating disaccharide units of N-acetylglucosamine and glucuronic acid that form
hydrated matrices (Figure 3). Unlike other GAGs, hyaluronan is not further modified in its
biosynthesis by sulfation or epimerization of the glucuronic acid moiety to iduronic acid.
Hyaluronan is also the only GAG to be synthesized in the cytoplasm at the plasma
membrane where the polymer extrudes extracellularly. Hyaluronan functions in synovial
fluids of articular joints to distribute the load during joint motion and protect cartilaginous
surfaces.17
Like chondroitin sulfate, dermatan sulfate consists of repeating disaccharide units
of sulfate substituted N-acetylgalactosamine and uronic acid, in this case primarily
iduronic acid. Additional enzymes involved in the biosynthesis of dermatan sulfate exist
for epimerization of glucuronic acid into iduronic acid and sulfation in patterns that are
found only in unusual species of chondroitin.17 The average molecular weight of dermatan
sulfate prepared from bovine intestinal mucosa is 25000 Da.19 Dermatan sulfate, like the
other GAGs, is involved with many biological activities including coagulation,
cardiovascular disease, tumorigenesis, infection, wound repair, and fibrosis. 20
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1.4 Polymers Approved as Drugs
1.4.1 Heparin
Heparin or unfractionated heparin (UFH) is a GAG that is well-known as an
anticoagulant and is widely used to treat or prevent clotting of the blood. Blood makes up
7-8% of total body weight and the average person has 9-12 pints of blood in the body.21
It is obvious that health problems related to blood disorders and clotting are serious and
have an important impact on human morbidity and mortality. Abnormal blood clots can
lead to deep vein thrombosis (DVT), pulmonary embolism (PE), heart attack, and stroke,
all of which can be fatal with just DVT alone resulting in 100,000 deaths annually in the
United States.21 Heparin is highly sulfated and very negatively charged at physiological
pH (Figure 4).6 Although found naturally in the human body, heparin for therapeutic use
today is derived from pig intestines.

Figure 4. An example of heparin polymeric GAG structure with the most common
repeating disaccharide unit consisting of a 2-O-sulfated iduronic acid residue and a 6-Osulfated, N-sulfated glucosamine residue with important functional groups shown in blue.

Heparin is a highly sulfated polysaccharide and its structure consists of alternating
disaccharide units of uronic acid and hexosamine residues.22 The uronic acid component
is predominantly L-iduronic acid in α-L-configuration and the hexosamine component is
D-glucuronic

acid, usually with N-acetylated glucosamine residues. The most common

repeating disaccharide unit consists of a 2-O-sulfated iduronic acid residue and a 6-O9

sulfated, N-sulfated glucosamine residue.22 Heparin’s mechanism of action for
anticoagulation is due to its ability to bind to antithrombin and accelerate antithrombinmediated inhibition of coagulation factors. Heparin chains contains the antithombinbinding region, a pentasaccahide sequence that has been rigorously studied and
characterized (Figure 5). All sulfate groups that are essential and important for highaffinity binding to antithombin have also been identified. 22 The high affinity
pentasaccharide sequence is expected to be present in 25-30% of chains. The average
chain length is between 40 and 50 monomer units and the polydispersity (calculated by
weight average molecular weight divided by number average molecular weight) is
between 1.3 - 1.4.23

Figure 5. The heparin pentasaccharide sequence is the key structural unit of heparin and
is responsible for anticoagulant activity via binding to anti-thrombin with key functional
groups shown in blue.
Although heparin is one of the oldest drugs and was discovered a century ago, it
took many years to move from the laboratory to the bedside. In 1922, William Henry
Howell introduced an aqueous extraction protocol for isolating heparin but after
commercial production, studies demonstrated that this preparation caused side effects
including headache, fevers, and nausea.22 In 1933, Charles Best and David Scott, with
the goal of further purification and reduction of side effects, outlined a protocol for isolating

10

a crude heparin preparation from bovine liver and purification, but the preparations were
not pure in the chemical sense, but rather free from toxic components. However, there
were problems getting consistent results from batch to batch which hampered clinical
progress. By 1949, Dr. Peter Moloney and Dr. Edith Taylor had patented a method that
obtained a greater yield of heparin at lower cost. It is noteworthy that before the exact
nature of heparin’s component carbohydrate residues and location of sulfate groups on
the polysaccharide chains were known, it was still successfully used in clinics as an
anticoagulant.22 Today, many issues must be considered regarding the development and
drug approval of heparins and heparin mimetics due to their polydisperse, heterogeneous
nature.24
Heparin originates in mast cell granules as the polysaccharide part of the
proteoglycan serglycin and upon degranulation, heparin is released from mast cells and
broken down by heparanase into fragments that are mostly between 5000 and 30000 Da.
Heparin used in medicine is a heterogeneous polydisperse mixture containing chains
from under 5000 Da to over 50000 Da.25 The U.S. Pharmacopeia Convention provides
acceptable ranges for the molecular weight distribution of heparin sodium indicating that
molecular weights above 24000 Da should represent no more than 20% of the sample,
the weight average molecular weight should be between 15000-19000 Da, and the ratio
of chains between 8000-16000 and 16000-24000 should be no less than 1.0.26
In 2008 Baxter Healthcare had to recall its heparin sodium for injection after acute
hypersensitivity reactions developed in patients receiving the drug and 81 deaths
involving at least one symptom of an allergic reaction or hypotension were reported.
There was a contaminant in the heparin that led to this fatal outcome, identified as over11

sulfated chondroitin sulfate (OSCS) that represented almost 30% by weight/weight in the
suspect heparin. OSCS that contains four sulfates per disaccharide unit is structurally
similar to heparin, but OSCS can directly activate the coagulation contact system, induce
the generation of anaphylatoxins in vitro, and activate kallikrein (which leads to profound
hypotension in pig models). Major efforts have been underway since the notorious
contaminated heparin issue came to light by researchers to develop screening an testing
procedures to detect polysulfated contaminants in heparin that may have unintended
pharmacologic consequences.27
Heparin possesses a myriad of biological activities, the most well known being
anticoagulation through the activation of antithrombin to inhibit clot formation. Heparin
also plays a role in proliferation by activating growth factors to induce cell growth,
differentiation, and morphogenesis. Heparin can bind to chemokines to modulate
inflammation and wound healing. Heparin also binds to enveloped virus glycoproteins to
modulate infection of target cells. Heparin is amongst the World Health Organization’s
Model List of Essential Medicines, but is associated with certain side effects that may limit
its use.28 Excess bleeding is a serious concern, although there is an antidote to heparin
available: protamine sulfate, which functions to reduce heparin’s blood thinning capability
by binding to it through electrostatic attraction and ionic bonding. Heparin-induced
thrombocytopenia (HIT) is an immune reaction that causes a drop in platelet count and
occurs in 3.5% of treated patients.4 Further, the polydisperse, heterogeneous nature of
heparin can cause variable patient response.5 Because of the omnipresent need for
anticoagulant therapies and the drawbacks associated with heparin use, developing
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alternative medications that target coagulation is an important goal for biomedical
researchers.5-8
1.4.1.1 Heparin’s Use in the Lung
Although heparin is primarily used as an anticoagulant, off-label use of inhaled
heparin and other anticoagulants has occurred in the treatment of asthma, acute lung
injury, and inhalational lung injury.29-37 This is because the inflammation pathways
associated with asthma are linked with coagulation pathways and microvascular thrombi
and alveolar fibrin depositions occur in acute lung injury. 31,36 There is crosstalk between
inflammation and coagulation when plasma containing clotting factors leaks from lung
capillaries due to inflammation. Further, fibrin deposits are increased by the decrease in
activity of the anticoagulant protein C system and inhibition of fibrinolysis (Figure 6).
Fondaparinux, hirudin, tissue plasminogen activator (tPA), and urokinase-type
plasminogen activator (uPA) have been shown to improve the disturbed hemostatic
balance in the lung, thereby diminishing allergic inflammation and asthma parameters
(Figure 7).36
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Figure 6. Inflammation and coagulation pathway crosstalk in the lung32

Figure 7. Fondaparinux inhibits factor Xa, hirudin inhbits thrombin, and tPA/uPA activate
plasminogen to improve the hemostatic balance in the lung and decrease inflammation
associated with asthma.32
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Acute lung injury is characterized by activated coagulation that may initiate or
exaggerate the injury, impair alveolar aeration and perfusion, and promote fibrosis. Acute
lung injury is also associated with attenuated fibrinolysis and enhanced breakdown and
decreased production of endogenous anticoagulants. The use of systemic anticoagulants
in acute lung injury has shown inconsistent results in clinical trials:


The PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) trial
showed that patients with a pulmonary cause of sepsis benefited more from
anticoagulation with recombinant human activated protein C (rh-APC) than
patients with sepsis caused by another source.



The CAPTIVATE (Community-Acquired Pneumonia Tifacogin Intra-Venous
Administration Trial for Efficacy) study suggested that infusion of
recombinant human tissue factor pathway inhibitor (rh-TFPI) improved
survival of patients with community-acquired pneumonia (CAP) but failed to
improve outcomes of patients with severe CAP.

However, higher lung concentrations may be necessary to have the desired effect on
pulmonary coagulation than is achievable with systemic administration. The risk of
bleeding increases with high systemic doses and there is questionable lung penetration
of anticoagulants administered systemically, providing support for direct, local
administration to the lung.31 A Phase 1 trial of nebulized heparin in acute lung injury
involving 16 ventilated patients showed that administration of nebulized heparin was
feasible and not associated with any serious adverse events, although higher doses did
increase activated partial thromboplastin time (APTT).35
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The benefits of heparin in treating inhalational lung injury have been shown in
multiple studies.29 Nebulized heparin with N-acetylcysteine has been shown to reduce
tracheobronchial cast formation and lung edema associated with inhalational lung injury
as well as decrease reintubation rates, the incidence of atelectasis (lung collapse), and
mortality in pediatric burn patients. In a retrospective trial of 52 patients on mechanical
ventilation vs. 11 control patients in Singapore, treatment with nebulized heparin, Nacetylcysteine, and salbutamol was found to be safe in that APTT, partial thromboplastin
time (PT), and platelet counts followed the same trend in both groups and no significant
increase in bleeding risk was observed for the treatment group.29
Although the potentially beneficial effect of inhaled heparin in experimental models
of acute lung injury has not yet been fully translated into clinical practice, the extensive
crosstalk between coagulation and inflammation suggests that targeting pulmonary
coagulopathy may influence the local inflammatory response. Preclinical studies provide
some evidence of the benefits of heparin delivered by inhalation in several animal models,
but clinical investigations in humans are sparse.32 More clinical trials are necessary to
evaluate the clinical utility of inhaled heparin and address what doses can achieve
maximal local effects without the risk of systemic complications, what should be the
duration of therapy, and if the underlying cause of the lung injury plays a role.32
1.4.2 Low Molecular Weight Heparins
Low molecular weight heparins (LMWHs) have now largely replaced UFH because
they produce a much more predictable anticoagulant response and are at least as
effective and as safe as UFH. 24 The FDA stipulates that each LMWH is unique and they
are not interchangeable due to significant structural, pharmacological, and toxicological
16

differences. Five criteria are used to determine similarity or difference among LMWHs:
physicochemical characteristics, source of UFH, structural composition, in vitro biological
activity, and in vivo pharmacodynamics profile.4 Because LMWH have high bioavailability
after subcutaneous (SC) injection, LMWH’s dose can be calculated based on body weight
and given SC without monitoring or dose adjustment. 24 The class of LMWHs includes:
dalteparin (Figure 8), enoxaparin (Figure 9), tinzaparin (Figure 10), and nadroparin (not
available in the United States).1
Although LMWHs are all derived from heparin and share a similar mechanism of
action, their molecular weight distributions are approximately one-third that of UFH and
vary from each other, resulting in differences in their activity against clotting enzymes
factor Xa and thrombin (factor IIa), their affinity for plasma proteins, and their half-lives.
LMWHs are distinct pharmacologic entities and have different properties such as: method
of preparation, molecular structure, half-lives, antithrombin and non-antithrombin
mediated activity, effect on thrombus, and dosing interval.1 FDA-approved indications for
these agents are product specific and have been evaluated extensively for a wide array
of indications such as acute coronary syndromes, DVT, PE, and prevention of venous
thromboembolism in high-risk populations.1
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Figure 8. Structure of dalteparin, showing anhydromannose in blue that is formed as a
result of the nitrous acid depolymerization in dalteparin’s production from unfractionated
heparin1

Figure 9. Structure of enoxaparin, showing the double bond in blue produced from the
benzylation and alkaline depolymerization used in production 1

Figure 10. Structure of tinzaparin, showing the double bond in blue introduced from the
enzymatic depolymerization with heparinase used in production 1

Three different depolymerization processes of porcine mucosal pharmaceutical
grade heparin preparations induce distinct changes to the heparin molecule, which results
in the unique molecular structure of each LMWH. The nitrous acid depolymerization used
to produce dalteparin induces the formation of anhydromannose. Benzylation followed by
alkaline depolymerization is used to produce enoxaparin and introduces a double bond.
Tinzaparin is made through enzymatic depolymerization with heparinase, which also
18

introduces a double bond. Each preparation has different proportions of the antithrombinbinding region (Figure 5) and linkage regions.1 Enoxaparin, for example, has a peak
average molecular weight of 4500 Da and polydispersity (weight average molecular
weight divided by number average molecular weight) between 1.1 and 1.5. Chains range
in length from 2 to 32 monomer units and fingerprints of 2 to 12 monomer unit long chains
account for 70 – 80% of the sample (with a peak average molecular weight of this portion
being 3600 Da). The high affinity pentasaccharide sequence is present in 15 to 25% of
chains in the sample. Enoxaparin contains odd and even chains and a specific proportion
of 8 known disaccharides.4
1.4.3 Fondaparinux
Another drug related to heparins is fondaparinux, which is not a heterogeneous
mixture like the others, but a single chemical entity consisting of solely of the
pentasaccharide sequence responsible for activity in the other heparins, with an O-methyl
group at the reducing end which prevents side reactions during synthesis (Figure 11).
Fondaparinux can be considered an ultralow molecular weight heparin and has a
molecular weight of 1728 Da, has no anti-thrombin activity, and is a specific factor Xa
inhibitor.38 Fondaparinux was first synthesized in 1986, but the preparation involves long
and complex chemical synthesis, making it expensive.38,39
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Figure 11. Structure of fondaparinux39

1.4.4 Pentosan Polysulfate Sodium (PPS)
Chemically and structurally related to GAGs, a heparin-like macromolecular
carbohydrate derivative known as pentosan polysulfate sodium (PPS), which has
anticoagulant and fibrinolytic effects, has been approved by the FDA (Figure 12).2 PPS is
indicated for the relief of bladder pain and discomfort associated with interstitial cystitis.
Although the mechanism of action is unknown, PPS has been shown to adhere to the
bladder wall mucosal membrane and may act as a buffer to control cell permeability and
prevent irritating solutes in urine from reaching cells.2 PPS is chemically known as β-Dxylan, (1-4), 2, 3-bis (hydrogen sulfate) sodium and is a mixture of linear polymers of β-1
to 4 linked xylopyranose, usually sulfated at the 2- and 3-positions and occasionally
substituted at the 2-position with 4-O-methyl-α-D-glucuronic acid 2, 3-O-sulfate. As a
requirement of the FDA, PPS should have a capillary electrophoresis pattern identical to
the low molecular weight distribution pattern of the innovator’s product (tradename:
Elmiron®).40 The highly reproducible fingerprint was achieved using a benzene-1,2,4tricarboxylic acid buffer (8.75 mM, pH 4.9) with indirect UV detection at 217nm (Figure
13).41 PPS used clinically in humans is confined to material manufactured by one
company, but there are three manufacturers of PPS for veterinary applications. 41
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Figure 12. Pentosan Polysulfate structure
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Figure 13. Capillary electropherogram of three batches (A, B, C) from one
manufacturer of pentosan polysulfate using a benzene-1,2,4-tricarboxylic acid buffer
(8.75 mM, pH 4.9) with indirect UV detection at 217nm 41

Fractions of pentosan polysulfate with higher degrees of sulfation are thought to
have better efficacy than less sulfated fractions, however, it is difficult to achieve high
levels of sulfation at consistent positions on the chain in low molecular weight ranges.
The degree of sulfation within known formulations can vary widely, which may lead to
variability in clinical efficacy.40 The number of xylose units in a PPS mixture can range
from 6 to 30 with on average a 4-O-methyl-D-glucuronic acid randomly attached every 8

22

to 10 xylose units and typically contain 15 to 17% sulfation. 40,41 PPS is synthesized from
xylan extracted from the bark of beech trees and other plants, which is then treated with
sulfating agents followed by sodium hydroxide to yield the sodium salt. Differences in the
manufacturing process can result in molecular differences of PPS mixtures, such as the
degree and position of sulfate groups.40,41 Clinical efficacy of sulfated carbohydrates is
well known to be affected by the type and position of sulfate groups, thereby showing the
need to fully control and characterize these molecules. 40 Drug registration authorities
insist that drug manufacturers provide analytical evidence of the molecular weights and
structural identity of active ingredients used in their preparations and that these criteria
remain consistent from batch to batch.41

1.5 Polymers that are Potential Drug Candidates
1.5.1 Semuloparin
A new class of heparins called ultra-low molecular weight heparins (ULMWHs) contains
the experimental drug semuloparin that has an average molecular mass of 2000 to 3000
Da. It is made up of oligosaccharides containing 1 to 11 heparin disaccharide subunits
with an average length of 8 subunits (Figure 14
Figure 14). The amino sugars of the oligosaccharides can be N-sulfated or Nacetylated and both the hexuronic acid (which is mainly iduronic acid) and the
glucosamine moieties can have O-sulfate groups at various positions. Most of the
molecules will have a double bond at the non-reducing end of the chain. Drug developers
looked carefully at attributes and liabilities of existing LMWHs with the goal of advancing
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the class to the next level and provide an optimized efficacy-bleeding balance for
semuloparin when compared with LMWHs.42
Semuloparin is generated using novel and proprietary manufacturing processes
with highly selective polymerization of heparin by the phosphazene base. Throughout this
process, anithrombin-binding sites significant for anticoagulant activity are protected from
destruction, and a distinct composition of the oligosaccharide chains with significantly
reduced average molecular weight of 2400 Da (compared with 3500 to 6000 Da for
LMWHs) can be obtained. The different structural features translate to a unique
anticoagulant and pharmacokinetic profile when compared with the LMWH class. 42
Semuloparin has been studied in a Phase 3 clinical trial for prevention of venous
thromboembolism (VTE) in major abdominal surgery, but was not able to demonstrate
non-inferiority to enoxaparin.43 However, the pivotal SAVE-ONCO trial found that
semuloparin reduced the incidence of VTE in chemotherapy patients and did not cause
an increase in major bleeding versus placebo.44 Unfortunately, in June of 2012 the
Oncologic Drugs Advisory Committee to the FDA was concerned that the results of the
SAVE-ONCO trial may not be clinically meaningful and questioned the study protocol
design. Ultimately, they voted almost unanimously against approval of semuloparin for
prophylactic prevention of VTE in cancer patients undergoing chemotherapy.45 By July of
the same year, semuloparin’s manufacturer withdrew the drug application and announced
that they would no longer seek marketing approval.46
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Figure 14. Structure of semuloparin

1.5.2 2-O, 3-O-Desulfated Heparin (ODSH)
Another therapeutically useful compound derived from heparin is 2-O, 3-Odesulfated heparin (ODSH).47-50 It is synthesized from USP porcine intestinal heparin by
cold alkaline hydrolysis, which removes the 2-O sulfate groups from iduronic acid
residues and the 3-O sulfate groups from the glucosamine residues of heparin. The Nsulfates, 6-O sulfates, and carboxylates on the heparin backbone remain intact (Figure
15).47 ODSH has low anticoagulant activity and broad anti-inflammatory activity,
demonstrating that most of the anti-inflammatory pharmacology of heparin is unrelated to
anticoagulant activity and the 2-O and 3-O sulfate groups can be removed to reduce
anticoagulant activity of heparin without impairing its anti-inﬂammatory abilities. Like
heparin, ODSH inhibits complement activation, binding to the leukocyte adhesion
molecule P-selectin, and the leukocyte cationic granular proteins azurocidin, human
leukocyte elastase (HLE), and cathepsin G.48 Heparin and ODSH disrupt Mac1(CD11b/CD18)-mediated leukocyte adhesion to the receptor for advanced glycation end
products (RAGE) and inhibit ligation of RAGE by its many proinﬂammatory ligands,
including the advanced glycation end-product carboxymethyl lysine-bovine serum
albumin, the nuclear protein high mobility group box protein-1 (HMGB-1), and S100
calgranulins. ODSH has been found to be more effective than heparin in mice studies in
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reducing selectin-mediated lung metastasis from melanoma and inhibits RAGE-mediated
airway inflammation from intratracheal HMGB-1.48Figure 15. ODSH (2-O, 3-O desulfated
heparin) structure

A phase II study evaluating ODSH in subjects with chronic obstructive pulmonary
disease (COPD) exacerbations was terminated in 2012 due to results showing evidence
of safety without efficacy. It was thought that because ODSH is a potent inhibitor of
cationic neutrophil proteases HLE and cathepsin G and inhibits the interactions
leukocytes with endothelium by inhibiting the attachment molecule P-selectin, it would
prevent neutrophil accumulation in areas of inflammation and be beneficial for treating
COPD exacerbations. Management of acute COPD exacerbations are treated the same
as they were for the past 40 years with bronchodilators, corticosteroids, and antibiotics.
Neutrophils play a prominent pathophysiological role in COPD exacerbations, so they and
their toxic oxidants and proteases represent previously unchallenged therapeutic targets.
Therefore, blocking neutrophilic influx from the vascular space into the airway and
neutralizing toxins such as HLE and cathepsin G would disrupt neutrophilic airway
inflammation and be a possible mechanism for ODSH to mediate COPD exacerbations. 51
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1.5.3 Phosphomannopentose Sulfate (PI-88)
Another drug candidate that is a heparan sulfate mimetic is a sulfated
oligosaccharide known as phosphomannopentose sulfate (PI-88).3 It is derived from
hydrolysis of extracellular phosphomannan that is produced by the yeast Pichia holstii,
which liberates a mixture of many oligosaccharides, and is then exhaustively sulfated.
The multi-component mixture is composed primarily (90%) of phosphomannopentose
and phosphomannotetrose sulfates, with the ratio between penta:tertra ranging from 2:1
to 3:2 (Figure 16). Di-, tri-, and hexa-phosphomannosulfates and a phosphotetrasaccharyl
amine compound are also present in PI-88 preparations. Sulfation of the mixture of
oligosaccharides does not go to completion, which results in a random, but reproducible,
mixture of sulfated oligosaccharides with the average degree of sulfation per mannose
unit ranging from 2.9 to 3.1. A comparison of properties for PPS and PI-88 including
ranges of average molecular weight is provided above (Table 1).3
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Figure 16. Structure of PI-88, which is predominantly composed (90%) of
phosphomannopentose (n=2) and phosphomannotetrose (n=1) sulfates in a ratio of
penta:tetrasaccharide ranging from 2:1 to 3:2. Average degree of sulfation ranges from
2.9 to 3.1 per mannose unit.

PI-88 mimics the structure of heparan sulfate and has the ability to inhibit the
heparan sulfate cleaving enzyme known as heparanase. Heparanase has been
implicated in tumor metastasis and recognition of cell surface heparan sulfate by
angiogenic growth factors plays an important role in angiogenesis. In vivo studies of PI88 revealed its capacity to inhibit tumor growth, metastasis, and angiogenesis. 3 PI-88 is
currently in a Phase 3 clinical trial for adjuvant treatment of patients with hepatitis related
liver cancer after surgical resection.52 In 2007, the FDA awarded Fast Track status to PI88 for the prevention of tumor recurrence following liver resection in patients with
hepatocellular carcinoma.53
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Table 1. Comparison of properties of heparin, LMWHs, fondaparinux, PPS, semuloparin,
ODSH, and PI-88.

Drug

Method of
Preparation

Molecular Weight
(Daltons)

Heparin (UFH)

purified from
porcine intestinal
mucosa

Peak Average: 16371
Number Average: 13537
Weight Average: 1800026
Mean: 60001
<3000: 3-15%
3000-8000: 65-78%
>8000: 14-26%55
Mean: 42001; 450056
<2000: 12-20% (16% avg)
2000-8000: 68-82% (74%
avg)
>8000: ≤18%56
Mean: 45001
<2000: <10%
2000-8000: 60-72%
>8000: 22-36%57

Dalteparin

Nitrous acid
depolymerization
1

Enoxaparin

Benzylation and
alkaline
depolymerization
1

Tinzaparin

Heparinase
digestion1

Fondaparinux

Long, complex
synthesis with Omethyl group at
reducing end38

Pentosan
polysulfate
sodium (PPS)

Bark of beech
tree; Semisynthetic2

Semuloparin

highly selective
polymerization of
heparin by
phosphazene
base42

2-O, 3-Odesulfated
heparin
(ODSH)

cold alkaline
hydrolysis48

Phosphormannopentose
sulfate (PI-88)

Yeast Pichia
holstii;
hydrolysis,
sulfation3

172839

4000-60002

HalfLife
(min)

Anti-Xa:
Anti-IIa
Activity
Ratio

60-9054

1.0426

1191391

2.71

1291801

3.81

1112341

2.81

900120039

Anti-Xa
only39

120016202

Weak,
(1/15 of
heparin)
2

Mean: 2400
2000-300042
Mean: 11700 ± 30048;
1050058
<6000: 30%
<10000: >60%58
Mean: 2400
1400-31003
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960120042

8042

11616348

low for
either

60-1623

Strong
fIIa
inhibitor;
no effect
on fXa3

2. Rationale for the Development of Low Molecular Weight Lignins (LMWLs)
As evidenced in the chapter above, developing polymers as drugs is challenging
work, but the therapeutic utility of polymers is promising for the treatment of many disease
states. As demonstrated for the approved polymers discussed above, it is possible to get
a polymer approved as a drug without full knowledge of its exact structure. This is
because structural characterization of polymers is difficult, and describing polymers’
molecular weight, chain length, linkage pattern, or degree of substitution with key
functional groups takes a large amount of data to determine acceptable average ranges
and assess similarity, not just a single value that must match. Varying degrees and depth
of information is known about each of the polymers discussed above, and there is no set
criteria for the evaluation of polymers stipulating what must be known before a polymer
can be approved as a drug.
For LMWHs, the FDA uses five criteria to describe their similarities and differences:
source of UFH it is synthesized from, physicochemical characteristics, structural
composition, in vitro biological activity, and in vivo pharmacodynamics profile.4 Two of
those criteria, the biological activity and pharmacodynamics, have been reported for the
promising polymers known as sulfated low molecular weight lignin (LMWLs), originally
developed as heparin mimetics, and will be summarized in this chapter. Less is known
about two of the other criteria, structural composition and physicochemical
characteristics, which are described in chapters 2 and 3 of this work. Determining the
structural composition, establishing physicochemical parameters, and analyzing
batch variability of a library of LMWLs to further their development as drugs is the
primary goal of this work.
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Sulfated LMWLs have shown good activity as anticoagulants, as well as promising
agents for treating emphysema and in xenotransplantation.5-9 These dehydropolymers of
cinnamic acid derivatives (caffeic (CA), ferulic (FA), and sinapic acid (SA) are chemoenzymatically synthesized as polydisperse, heterogeneous polymer mixtures of varying
chain length, linkage, and sulfation patterns. Before sulfation, the LMWLs are abbreviated
CD, FD, and SD based on the corresponding monomer and serve as precursors of the
sulfated LMWLs, abbreviated in kind as CDS, FDS, and SDS. Similarities between
heparin and sulfated LMWLs include: anticoagulant activity, polymeric structure, sulfation,
and negative charge. However, notable differences are evident in the non-sugar, aromatic
backbone of sulfated LMWLs vs the GAG backbone of heparin, the lesser degree of
sulfation in LMWLs, and the 2-5 times reduced average molecular weight of LMWLs
(3,000-6,000 Da) vs heparin (15,000 Da).5-8,59
LMWLs are reported to have potent anticoagulant activity, primarily through
allosteric inhibition of thrombin by binding in exosite II.5 Heparin competes with sulfated
LMWLs for binding to clotting factors Xa and XIa.60 Sulfated LMWLs also inhibit a select
group of heparin-binding serine proteases with measured IC50 values (Table 2).60 CDS
was the most potent LMWL by at least a factor of 2 in inhibiting thrombin (IC 50= 18 nM),
factor Xa (IC50= 34 nM), and factor XIa (IC50= 22 nM).60
Both unsulfated and sulfated LMWLs increase the time it takes blood to clot,
although the latter is more potent, as measured by activated partial thromboplastin time
(APTT) and prothrombin time (PT) clotting assays (Table 2). While all LMWLs were more
effective at increasing PT than LMWH, LMWH was more potent than LMWLs at
increasing APTT. Again, CDS was the most potent LMWL at increasing APTT and PT. 8
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Table 2. Concentrations of LMWLs necessary to increase the clotting time 2 times over
baseline PT or APTT clotting time in human plasma [Adapted from Ref 24]
Heparin-Binding
Serine Protease
Cathepsin G

CDS
(nM)
232 ± 10

FDS
(nM)
91 ± 7

SDS
(nM)
105 ± 7

Heparin
(nM)
42 ± 7

Human Leukocyte
Elastase (HLE)

11 ± 2

9±2

17 ± 1

1.1 ± 0.1

Plasmin

240 ± 30

760 ± 20

1290 ± 60

No inhibition

Thrombin

18 ± 2

29 ± 2

94 ± 4

No inhibition

Factor Xa

34 ± 5

74 ± 8

121 ± 26

No inhibition

Factor IXa

3380 ± 64

490 ± 16

>28,500

No inhibition

Factor XIa

22 ± 2

105 ± 11

176 ± 11

No inhibition

Table 3. 50% inhibitory concentration (IC50) values measured through chromogenic
substrate hydrolysis assays for sulfated LMWLs and heparin [Adapted from Ref. 60]
2 x PT (ug/mL)

2 x APTT (ug/mL)

CD

98.1

±

0.7

24.9

±

2.3

FD

161.3

±

2.7

39.5

±

0.8

SD

212

±

2.9

32.1

±

1.5

CDS

42.1

±

0.3

13

±

5

FDS

63.4

±

0.1

18.3

±

1.9

SDS

104.6

±

3.9

22.6

±

1.1

LMWH

142.1

±

3.6

5.9

±

3

Throughout this work, emphasis will be placed on the development of one LMWL
in particular: the sulfated dehydropolymer of caffeic acid (CDS), which has been
evaluated in animal models for the treatment of emphysema.9 CDS has shown promising
activity for treating emphysema through in vitro inhibitory activity against elastase,
oxidation, and inflammation.61 Emphysema is a manifestation of chronic obstructive
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pulmonary disease (COPD) which progressively destroys alveolar structures, causes
breathing difficulty, chronic cough, physical and functional disability, and eventually death.9 Bronchodilators and inhaled corticosteroids are used for management of COPD
symptoms, but no drugs are approved for the prevention, intervention, or resolution of this
life-threatening disease. COPD effects 13 million people and costs $50 billion annually in
the US, where it is the third leading cause of death. The LMWL CDS is a promising, novel
drug for the treatment of emphysema.9
Induced proteolysis, oxidative stress, and inflammation are thought to be the major
mechanisms that lead to emphysema, but the pathobiology of alveolar septum destruction
and loss is not fully understood.9 Inhibition of a single mechanism can be compensated
for by one of the other interacting mechanisms, therefore drugs that target multiple
mechanisms are likely to be more effective at treating emphysema. CDS is a versatile,
potent, triple-action inhibitor of induced elastolysis, oxidation, and inflammation at low
micromolar concentrations in vitro.9 CDS exhibited in vitro anti-human neutrophil elastase
(HNE) activity with an IC50 of 0.43 ± 0.04 µM, anti-chemical oxidative activity with an IC50
of 3.52 ± 0.14 µM, and anti-inflammatory activity with an IC50 of ~10 µM.61
A rat model of emphysema involves orotracheal (OT) instillation of human sputum
elastase (HSE) and cigarette smoke extract (CSE) that induces elastolysis, oxidative
stress, inflammation, airway luminal neutrophil infiltration, lung functional impairment of
exercise endurance, and morphological airspace enlargement. 9 CDS was administered
in this model in both a preventative (before the HSE/CSE instillation) for acute features
of emphysema and interventional (after the HSE/CSE instillation) fashion. CDS was found
to inhibit induced elastolysis, oxidative stress, and inflammation and attenuate the
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development of emphysema with a one-time dose of 30 ug/kg when administered
between 2 hours before to 24 hours after HSE/CSE instillation. Doses of 30 ug/kg of CDS
maintained their preventative effects in the lungs for 6 hours, whereas doses of 100 ug/kg
were able to extend their effect to 24 hours. CDS’s duration of action of up to a day after
pulmonary administration was likely achievable because the LMWL polymer has higher
molecular weight that enables sustained retention in the lung due to slow absorption and
resistance to degradation.9
Interventional administration one week after the HSE/CSE instillation enabled
more a clinically realistic model of CDS’s ability to limit the progression of emphysema. 9
A week after HSE/CSE instillation, CDS was dosed at 30 ug/kg every two days for three
weeks and rats were found to be capable of maintaining ~60% healthy exercise
endurance and airspace. This suggests that CDS can still provide effective intervention
in the development of emphysema even when the administration occurs up to a week
after emphysema has been induced. CDS was also administered in the rat model
subcutaneously, but was found to be ineffective when administered by this route,
suggesting a need for local delivery to the lung.9
CDS’s prophylactic attenuation of elastase-induced emphysema following
pulmonary administration in rats is also an activity exhibited by heparin. 9 Heparin’s
attenuation of emphysema is attributed to its anti-elastase activity and it is not considered
directly anti-oxidative, whereas CDS demonstrates both inhibitory activities. CDS is much
more potent than heparin at attenuating emphysema, with an effective molar dose of 9
nmoles/kg versus ~200 nmoles/kg for heparin.9
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Although impressive and promising in vitro biological activities and in vivo
pharmacodynamics have been reported in support of the development of LMWLs as
drugs, there are still significant questions regarding their physicochemical characteristics
and structural composition. Thus far, the reported molecular weights for the sulfated
LMWLs (CDS, FDS, and SDS) were derived from GPC-HPLC analysis of their unsulfated
LMWL precursors. This work attempts to define the structural composition of sulfated
LMWLs directly through SEC-HPLC analysis and definition of the molecular weight
distribution patterns. Well defined molecular weight distribution patterns are a hallmark of
the polymer drug development process, as described for the therapeutically useful
polymers in the introductory chapter. Not only is knowledge of the molecular weight
distribution useful to gain drug approval, it is also necessary for calculating accurate
doses of pharmaceuticals. Molecular dynamics simulations were conducted as part of this
work to model the LMWLs behavior in solution.
Another goal of this work is to describe the physicochemical properties of the
LMWL library. Elemental analysis was performed on two batches of CDS to determine
elemental content, batch variability, and proportion of types of linkages. Octanol-water
distribution coefficients were measured to estimate the hydrophobicity of the LMWL
polymers that contain a duality of features: charged functional groups and aromatic
backbones. Determining physicochemical characteristics is another piece of the puzzle
needed to provide a complete picture of CDS and advance its development as a drug
candidate. The structural composition and physicochemical properties described
in Chapter 5 for the sulfated LMWLs represents the most comprehensive and
accurate information we have to date about how these polymers exist in reality.
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3. Structural Characterization of LMWLs
3.1 Background on Molecular Weight Distribution of Polymers
Polymers exist as repeating units of monomers bonded together in long chains
and often as polydisperse, heterogeneous mixtures of different chain lengths, linkage
patterns, functional group substitutions, and dynamic conformations. As such, they
cannot be described as a single distinct chemical entity and characterizing their properties
is more complex and prone to error than pure small molecules which commonly make up
the active ingredient in pharmaceuticals. Molecular weights of polymers are denoted by
distributions of chain length and acceptable percentages of the heterogeneous mixture
must fall into similar distribution patterns to ensure minimal batch variability. Values of
molecular weights are calculated averages from all the chain lengths in the sample and
can be described differently: number average molecular weight (MN), weight average
molecular weight (MW), or peak average molecular weight (MP) (Figure 17).
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Polymer Molecular Weight Distribution

Figure 17. SEC-HPLC profile of a polymer and apparent molecular weight distribution
estimates, highlighting the difference between peak (MP), number (MN), and weight (MW)
average molecular weight
Number average molecular weight, MN, refers to the statistical average molecular
weight of all the polymer chains, and can be calculated by:
MN = (ƩNiMi) / (ƩNi)
where Mi is the molecular weight of a chain and Ni is the number of chains of that
molecular weight. There are equal numbers of molecules (N) of either side of the MN in
the distribution. For homogeneous polymer samples, the MN is 1.
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Weight average molecular weight, MW, takes into account the molecular weight of
a chain in determining contributions to the molecular weight average. The larger the
chain, the more it will contribute to Mw. Mw can be calculated by:
MW = (ƩNiMi2) / ( ƩNiMi)
where Mi is the molecular weight of a chain and Ni is the number of chains of that
molecular weight. There is equal weight of molecules of either side of the MW in the
distribution.
The peak average molecular weight, MP, represents the weight of the most
commonly found chain in the sample and is the statistical mode of the molecular weight
distribution. It can be calculated by determining the molecular weight corresponding to
the maximum absorbance (top of the peak) on analytical techniques such as size
exclusion chromatography measuring UV absorbance.
The polydispersity index measures the broadness of the molecular weight
distribution or the heterogeneity of a mixture and is calculated by:
Polydisperisity index = MW / MN
Larger polydispersity indexes correspond to broader molecular weight distribution ranges.
Monodisperse polymers with all chain lengths in the sample being equal have a
polydispersity of 1.62 In 2009, the International Union of Pure and Applied Chemistry
(IUPAC) issued recommendations replace the term monodisperse with “uniform” and
polydisperse with “non-uniform.” Further, they suggest replacing the polydispersity index
with the new term “dispersity,” coined to denote the measure of dispersion of
macromolecular species in a sample of polymer.63
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Developing polymers as drugs requires setting standard distributions of molecular
weight to ensure equivalency from batch to batch and manufacturer to manufacturer.
Acceptable reference ranges for other properties, such as dispersity, must also be
established for comparison. While drug approval of polymers may require more difficult
and detailed characterization than small molecules, the success of the polymeric drugs
discussed above illustrates the utility of developing polymers as pharmaceuticals.
3.2 Previous SEC-HPLC Studies on Unsulfated LMWLs
Thus far, the reported molecular weights for the sulfated LMWLs (CDS, FDS, and
SDS) were derived from SEC-HPLC analysis of their unsulfated LMWL precursors (CD,
FD, and SD) (Table 4). Elemental analysis was used to determine the degree of sulfation
of CDS, FDS, and SDS, and the apparent molecular weights of CD, FD, and SD were
combined with the sulfur content from elemental analysis to estimate the molecular weight
of the sulfated LMWLs. The work in this thesis is the first effort to measure the sulfated
LMWLs molecular weight distribution profile directly on SEC-HPLC, rather than derive the
molecular weight from the unsulfated precursors.
Table 4. Literature values of molecular weight reported for LMWLs and control
anticoagulants
Reported Avg MW
CDS
33205
FDS
41205
SDS
35505
CD
28008
FD
36508
SD
29908
Heparin
12000 - 15000 (13000)5
4500
<2000 daltons ≤20%
Enoxaparin
2000 to 8000 daltons ≥68%
>8000 daltons ≤18%56
Fondaparinux
172839
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Because both LMWLs and heparin have complex structures (polydisperse,
heterogeneous mixtures) their physicochemical behavior and molecular weight are
difficult to predict and measure. However, characterizing these polymers is important to
ensure minimal batch-to-batch variability, calculate accurate doses, and achieve
consistent, predictable patient responses. It is the goal of this work to develop methods
to better characterize sulfated LMWLs, such as determining the proper conditions to get
the most accurate data from size-exclusion chromatography (SEC) performed on a highpressure liquid chromatography (HPLC) system.
3.3 Synthesis
The dehydrogenation polymers of cinnamic acid derivatives: caffeic acid (CA),
ferulic acid (FA), and sinapic acid (SA)
were synthesized by the “zutropfverfahren”
procedure as described previously in
literature to form the LMWLs.8

Briefly,

200mL of 25mM cinnamic acid derivative
and 100mL of 75mM hydrogen peroxide
were added dropwise, slowly into a three
neck round bottom flask in dark containing
a solution of 10mg horseradish peroxidase
(HRP) in 50mL of buffer with stirring. The
buffer used in all cases was 10mM sodium
Figure 18. Glassware set up of LMWL
synthesis procedure

phosphate, pH 8.0 and the reaction was
performed at room temperature (25°C).
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Three addition aliquots of 75mM hydrogen peroxide were added dropwise over the next
72 hours at the rate of ~1 aliquot per day (Figure 18). At the end of approximately 80
hours, the solution was freeze dried, redissolved in high purity water, and filtered
repeatedly by centrifugation through molecular weight cut off filters of 5000 Da to remove
salts and low molecular weight species. The final solution was washed with ether and
freeze dried, resulting in a dark brown powder.8
This sodium salt of each dehydropolymer was then sulfated with trimethylaminesulfur trioxide complex by dissolving 500mg of the dehydropolymer in 50mL
dimethylformamide (DMF) with 1 gram of trimethylamine-sulfur trioxide complex and
stirring for 24 hours at 60°C. DMF was then removed in vacuo and the remaining product
taken up in 30% aqueous sodium acetate. The sodium salt was then precipitated using
~10 volumes of cold ethanol and the precipitate was further purified by repeated filtration
by centrifugation through molecular weight cut off filters of 10000 Da and freeze dried to
yield a dark brown powder of the sulfated LMWLs.8
The oxidative polymerization mechanism of the LMWL synthesis includes a
transitional state of unstable radicals (I, II, III, IV) that combine to form the variety of
linkages between monomers in the final product (Figure 19). For example, radicals I and
II combine into a β-O-4 linked dimer ( Figure 20), radicals II and IV combine resulting in
a β-5 linkage (Figure 21), and radical IV can react with itself to form a β-β linkage. 5-5
and 5-O-4 linked monomers are also possible, but the β-O-4 and β-5 linkages are thought
to predominate in the final product.8
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Figure 19. Schematic of radical polymerization of caffeic acid and radical transition state
that results in varying linkage pattern characteristic of LMWLs
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Figure 20. Radicals I and IV combining into β-O-4 linked dimer

42

Figure 21. Radicals II and IV combining into β-5 linked dimer
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3.4 Size Exclusion Chromatography of LMWLs
SEC-HPLC is a powerful tool for the separation, identification, and quantification
of species in a mixture. The system works by pumps that send pressurized liquid solvent
with the sample through a column packed with porous beads made of an adsorbent
material. Each component in the sample mixture interacts with the adsorbent material
differently, resulting in varied elution times and allowing separation. A schematic of an
HPLC system is provided showing the flow of the degassed mobile phase from its
reservoir by the pumps to the autosampler where analyte is injected through the column
into the detector and the graph output on the computer (Figure 22).64 On our Shimadzu
HPLC system an ultra-violet (UV) SPD-10AVP detector was used and absorbance
monitored at 206 and 280 nm.

Figure 22. Schematic diagram of high-pressure liquid chromatography system
Larger molecular weight species are able to flow through the column without
getting caught in pores and elute faster than smaller molecular weight species. Smaller
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molecular weight species can get into the pores of the packing material in the column
resulting in a longer path length and increased time to elution. The elution volume is
calculated by multiplying the flow rate by the time of elution and separates the mixture
according to molecular weight and can be used to identify the species in a mixture. The
height of the peak indicates the concentration or quantity of species in the sample. 64
A library of LMWLs was analyzed by SEC-HPLC along with control polymers
heparin and enoxaparin (a low molecular weight heparin; LMWH) to determine number,
weight, and peak average molecular weight and polydispersity. Both sulfated and
unsulfated polymers were tested from 3 starting monomer acids: caffeic acid (CDS –
sulfated; CD – unsulfated), ferulic acid (FDS; FD), and sinapic acid (SDS; SD). Three
independently prepared batches of both CDS (CDSMT1; CDSMT2; CDSBH) and FDS
(FDSMT, FDSJT, FDSBH) were also analyzed to determine batch variability.
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3.4.1 Method Development
SEC-HPLC studies began on a Shodex Asahipak GS-HQ520 column, which
resulted in elution order of the polystyrene sulfonate (PSS) standards that violated the
principle of SEC-HPLC columns (Table 5). A new Shodex Asahipak GS-HQ320 column
was purchased with a Pullulan cut-off limit of 40,000, >19,000 theoretical plates, 6 micron
particle size, 30 cm in length, and a minimum pore
size of 400.65 The polystyrene sulfonate (PSS)
standards that were used had molecular weights of
208, 4230, 6530, 13200, 14900, and 32900 (Figure
23). However, the 208 molecular weight (MW) PSS
standard was below the maximum pore size of 400
and was found to have varied elution volumes and
Figure
23.
Structure
of
polystyrene sulfonate standards
used for SEC-HPLC calibration

due to this was not included in the calibration curve
calculations. Fondaparinux was also used as a
control in initial studies but found to have non-

reproducible elution volume, likely due to its small molecular weight of 1728 g/mol not
being that much larger than the maximum pore size of 400.
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Table 5. Attempted solvents for mobile phase in SEC-HPLC studies
Attempted Solvent for Mobile Phase of CDSO3 SEC-HPLC with GS-HQ520
Column
Components
Flow Rate
Results
70:30 0.1 M
NaCl in H2O:
0.75mL/min
No peaks/too broad
ACN
Dual peaks of PSS, nonPSS does not come
50:50
reproducible sample peaks
out in order that
0.5mL/min
water:ethanol
(Figure 24Error! Not a valid
adheres to principle
bookmark self-reference.)
of SEC columns
(Figure 25)
70:30
0.4mL/min
Broad/dual peaks
water:ethanol
0.1 M NaCl in
0.5mL/min
No peaks/too broad
H2O

500000

SEC-HPLC Dual/Inconsistent Peak Profiles on
GSHQ520 Column
13200 MW PSS standard

400000

Absorbance

43uM CDS MT1
300000

45uM CDS BH

200000
100000
0
8

-100000

9

10

11

12

13

14

15

16

Elution time (minutes)

Figure 24. SEC-HPLC profiles showing dual peaks of polystyrene sulfonate (PSS)
standard of 13200 Da, as well as inconsistent results for two batches of CDS. Mobile
phase used was 50:50 water: ethanol at 0.5mL/min and data was acquired on a
GSHQ520 column
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SEC-HPLC Profile: Misordered PSS Standards
600000
6530 MW PSS Standard
13200 MW PSS Standard
14900 MW PSS Standard
32900 MW PSS Standard

Absorbance

500000
400000
300000
200000
100000
0
10

10.5

11

11.5

12

12.5

13

Time (minutes)

Figure 25. PSS standards coming out in order that defies the principle of SEC with the
largest standard of 32900 Da eluting last & the 6530 Da standard eluting after the 13200
Da & 14900 Da standards. Acquired on GSHQ520 column and 0.5mL/min water as
mobile phase.
The known molecular weight standards elute at measurable volumes and create a
calibration curve that can be used to calculate unknown molecular weights based on their
elution volume measured on the same system with the same mobile phase. The unknown
molecular weight samples appear as a peak and the molecular weight can be calculated
based on the elution volume at each absorbance point. These molecular weights at each
point can then be averaged over relevant ranges to describe the molecular weight
distribution profile.
A PSS standard of MW below that of the predicted MW of the LMWLs would have
increased the validity of the calibration curve in the range of the LMWLs, but with the
elimination of the 208 MW PSS standard due to column constraints, 4230 was the next
smallest available. Due to the structure of the PSS standards containing an aromatic
backbone, it is likely that they are a better representation of our sulfated LMWL molecules
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which share the aromatic backbone feature and a less similar representation of heparins
that have a different polysaccharide backbone. This could indicate that the calculated
molecular weights of the sulfated LMWLs is arguably more accurate than the calculated
molecular weights of heparins tested. Previous studies had calculated the molecular
weight of the sulfated LMWLs based on extrapolation of SEC-HPLC results from the
unsulfated LMWLs coupled with elemental analysis of the sulfated LMWLs: CDS – 3320
g/mol; FDS – 4120 g/mol; SDS – 3550 g/mol; CD – 2800 g/mol; FD – 3650 g/mol; SD –
2990 g/mol.5,8
Because of the overestimation of the molecular weights across the board with all
polymers and due to the known possibility of hydrophobic interactions, we hypothesized
that aggregation was likely occurring in the LMWL samples and resulting in falsely
elevated apparent molecular weights. The pH of the mobile phase was increased to 11
because the basicity would result in negatively charged carboxylic acids groups on the
polymers that in theory would cause electrostatic repulsion between polymer chains and
reduce their tendency to aggregate. Additionally, sodium chloride salt was included in the
mobile phase to disrupt ionic interactions between the polymers and reduce aggregation
due to the presence of sodium and chloride ions. Finally, the addition of two different
surfactants, Tween 80 and Triton x-100, was employed to disrupt aggregation (Figure
26). Three concentrations of Tween 80 were utilized to detect differences in polymer
behavior across a range of surfactant concentration.
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Figure 26. The chemical structures of Tween 80 and Triton X-100, which are
polydisperse, heterogeneous non-ionic surfactants

To assure that the chromatography was performed under dilute conditions, a range
of concentrations of heparin and CDS were analyzed on the HPLC system with and
without 0.02% Tween 80 in the mobile phase. Maximum absorbance was plotted vs the
known concentrations to get a standard curve used to back calculate the concentration
of polymer in SEC-HPLC studies (Figure 23). Concentrations for CDS: 50, 100, 200, 400,
1000, 3000 uM and Heparin: 50, 100, 200, 400, 700, 1000 nM. Calibration curves based
on the known concentrations of CDS and heparin measured on our SEC-HPLC system
are presented in Figure 27.
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Known Concentrations of CDS and Heparin – Calibration Curves
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Heparin without Surfactant Calibration Curve

0
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Heparin with 0.02% Tween 80 Calibration
Curve
40000
35000
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0
0
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CDS without Surfaction Calibration Curve

CDS with 0.02% Tween 80 Calibration
Curve
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40000

400000

Absorbance

Absorbance

500000

300000
y = 172.74x + 989.85
R² = 0.9969

200000
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0
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R² = 0.9924
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0

0
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2000
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-10000
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0

2000
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Figure 27. Known concentrations of CDS and Heparin calibration curves used for SECHPLC
Calculations revealed that there were 255 moles of tween per mole of heparin in
the SEC-HPLC study with 0.02% tween 80 in the mobile phase. In contrast, there were 9
moles of CDS per mole of tween in the same experiment. While CDS chromatography
was therefore known to have been performed under dilute conditions whereas heparin
was not, possible explanation for the overestimation of the molecular weight of heparin
revealed in the study could be due to hydrogen bonding interactions between tween and
a chain of heparin. If several (up to 255) tween molecules were associated with heparin,
the apparent molecular weight of heparin could be increased by a factor of the molecular
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weight of tween (1310 g/mol). For instance, the literature indicates the average molecular
weight of heparin is 15,000 g/mol. In our study, without surfactant the MW of heparin was
calculated to be 18,976g and with 0.02% tween 80 was 29,516g. We can then attempt to
attribute the difference to the presence of tween by: 29,516g – 18,976g = 10,540g.
10,540g / (1310 g/mol tween) = 8 moles of tween associated with heparin causing it to
have a 2x overestimated (29,516g/mol) MW when 0.02% tween is used in mobile phase.
The HPLC conditions required the use of a higher concentration of heparin than CDS
because CDS contains aromatic groups that can be monitored at 232 – 280 nm
wavelength whereas heparin does not contain aromatic groups. Heparin absorbance was
monitored at 206 nm due to its lack of structural characteristics that would absorb at a
higher wavelength, and monitoring at 206 nm can be subject to interference from a variety
of species. Although dilute conditions are ideal in SEC-HPLC studies, a higher
concentration of heparin is needed to achieve adequate absorbance signal on the HPLC.
Calibration curves for all five mobile phases were established individually with
polystyrene sulfonate standards of known molecular weights (Figure 28). The change in
elution volumes from around 6-7mL for molecular weight species of ~3000-4000 g/mol,
to 12-13mL is due to the experiments being performed on different days where back
pressure in the pump can differ. Because PSS standards were shot in triplicate for each
experiment and mobile phase, comparable calculated molecular weights were able to be
ascertained and the differing scales of the x-axes in (Figure 28) was accounted for and
did not affect the data analysis. Elution volumes can change over the life of a column due
to differing pressure generated by the pumps and changes in the actual flow rate
responsible for sending the liquid mobile phase through the system. Drifting retention
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times may also be due to equilibration issues in the column, as retention times are
susceptible to the amount of water adsorbed in the silica surface of the column packing
material.66
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SEC-HPLC Calibration Curves of Polystyrene Sulfonate Standards (PSS)
without Surfactant
0.01% Tween 80
PSS Calibration Curve with 0.01% Tween 80
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Figure 28. SEC-HPLC Calibration Curves Polystyrene Sulfonate Standards (PSS) of
known molecular weight in various mobile phases used to calculate unknown molecular
weight of library of LMWLs
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3.4.2 SEC-HPLC Results and Discussion
Chromatograms, calculated peak average molecular weight (MP), number average
molecular weight (MN), weight average molecular weight (MW), polydispersity, and
molecular weight distribution for the sulfated LMWLs (CDS, FDS, and SDS), the
unsulfated LMWLs (CD, FD, and SD), and control anticoagulants (heparin and
enoxaparin) are presented below. Average SEC-HPLC profiles were acquired using four
mobile phases of increasing concentrations of the surfactant Tween 80 (0-0.05%).
Molecular weight distributions were calculated for chains under 6000 Da, between 6000
and 10000 Da, and above 10000 Da. While the 6000-10000 Da division was calculated
for all molecules to allow for comparison, more appropriate ranges were calculated in
addition for larger (heparin) and smaller (enoxaparin and SDS) when warranted.
3.4.2.1 CDS and Control Anticoagulants
Firstly, CDS, heparin, and enoxaparin will be discussed together for comparison
and insight into these analogous polymers’ contrasting (heparin and CDS) and
comparable (enoxaparin and CDS) behavior in solution.
CDS had a bimodal molecular weight distribution pattern when no surfactant was
used in the mobile phase (Figure 29). The MP of 9121 Da calculated from the PSS
standard curve without surfactant is almost three times greater than the previously
reported molecular weight for CDS of 3320 Da (Table 6). There is a second MP of ~23000
Da visible in the profile of CDS when surfactant is not present in the mobile phase that
disappears in the profiles acquired in the presence of surfactant (Figure 29). This
indicates that the larger molecular weight species causing the second mode in the profile
acquired without surfactant is likely several smaller molecular weight chains aggregating
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together and causing a falsely elevated apparent molecular weight. Aggregation of CDS
is supported by the addition of surfactant not only resulting in lower MP and MN values,
but also in the change of shape of the molecular weight distribution profile from bimodal
to unimodal.

Figure 29. SEC-HPLC chromatogram of CDS showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used
in the mobile phase.

CDS contains an aromatic backbone which could logically cause chains to
aggregate together through energetically beneficial hydrophobic interactions such as ππ stacking in the absence of surfactant. Addition of surfactant could also logically break
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up this aggregation and cause the larger molecular weight species to disperse, resulting
in the unimodal profile of CDS seen when Tween 80 is used in the mobile phase of HPLC.
The molecular weight distribution profile for heparin can be contrasted with that of
CDS because the heparin peaks are shifted to the right when surfactant is added whereas
they move to the left with CDS (Figure 30). This means that the molecular weight of
heparin is overestimated to a greater degree in the presence of surfactant, whereas the
molecular weight of CDS was better estimated in the presence of surfactant. Heparin’s
MP, MN, and MW values are increased when surfactant is present, whereas CDS’s MP and
MN values are decreased in the presence of surfactant (Table 6).
Table 6. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of CDS and heparin
MN
MW
CDS
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

9121
5582
5742
4754

Heparin
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

MP
18976
24988
29516
21362

(~10% error)

(~10% error)

8604
6567
5513
5231
MN

12242
12606
14217
9210
MW

(~10% error)

(~10% error)

16410
27697
26624
19795

18267
27506
30220
22616

± 170
± 1219
± 512
± 630

±
±
±
±

726
727
121
984
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1.42
1.92
2.58
1.76
Polydispersity
1.11
0.99
1.13
1.14

Figure 30. SEC-HPLC chromatogram of heparin, showing SEC-HPLC conducted with no
surfactant and varying concentrations of Tween 80 in the mobile phase.
Although the MP and MN values for CDS appear to follow a trend of indirect
variation with increasing concentration of Tween 80, this trend is not statistically
significant. No such trend exists or is also statistically insignificant for the weight average
molecular weight of CDS or any of the molecular weight averages for heparin.
Polydispersity is relatively the same for heparin with and without surfactant, where
as it is increased in the presence of surfactant for CDS. Whatever chains that were
aggregated when no surfactant was present, are able to disperse and contribute their
own individual molecular weight to the average when surfactant is present. These
“additional” free chains could explain why the polydispersity index value is increased
when surfactant is present.
The molecular weight distribution breakdown for CDS also changes in the
presence of surfactant following the same trend as before (Figure 31). The percent of
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small chains (less than 6000 Da) nearly doubles when surfactant is added and the percent
of medium chains (6000-10000 Da) and large chains (greater than 10000 Da) both
decrease by almost half.

Figure 31. Molecular weight distribution of CDS in the presence and absence of different
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis

The same molecular weight distribution cut offs are provided for heparin, but
changes are hard to visualize because the majority of chains in heparin have a molecular
weight greater than 10000 Da (Figure 32). Because the FDA requires that the ratio of
chains between 8000-16000 and 16000-24000 in heparin samples be no less than 1.0, a
breakdown based on those numbers was calculated in addition (Figure 33).26

59

Figure 32. Molecular weight distribution of heparin in the presence and absence of
different concentrations of surfactant used in the mobile phase for SEC-HPLC analysis

Figure 33. Larger molecular weight distribution of heparin in the presence and absence
of different concentrations of surfactant used in the mobile phase for SEC-HPLC analysis
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The percent of chains with molecular weight between 16000-24000 Da decreases
from 69% when no surfactant is present to ~30% in the presence of surfactant (Figure
33). However, the percent of larger chains (greater than 24000 Da) increases from 12%
when no surfactant is present to ~30-40% in the presence of surfactant. It is the increase
in the percent of larger chains that contributes to the overall increase in MP, MN, and MW
values. The long chains of heparin may be subjected to more physical aggregation in the
presence of surfactant due to the simple fact that added surfactant adds more molecules
into the solution and can increase the likelihood of polymer chains to bump in not only to
one another but also into molecules of the surfactant itself as well. If these long chains
become entangled with one another or trap surfactant molecules within their aggregate,
the apparent molecular weight will be falsely elevated, which is what we see in the SECHPLC profiles of heparin (Figure 30).
Table 7. Attempted mobile phases used in SEC-HPLC and resulting percent
overestimation of the literature value for molecular weight of CDS and heparin
Mobile Phase

Overestimated of literature MW by x Fold
CDS

Heparin

No Surfactant

2.7

1.3

0.01% Tween 80

1.7

1.7

0.02% Tween 80

1.7

2.0

0.05% Tween 80
1.4
1.4
There is a contrasting behavior of the analogous polymers CDS and heparin in
solution. Whereas the apparent molecular weight of CDS decreases in the presence of
surfactant, the apparent molecular weight of heparin increases in the presence of
surfactant (Table 7). There is no correlation of surfactant concentration with amount of
molecular weight overestimation; the effect of surfactant on apparent molecular weight is
concentration independent and similar for all concentrations used (0.01-0.05%).
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3.4.2.2 Enoxaparin
The second control anticoagulant, enoxaparin, behaves much like CDS in that the
SEC-HPLC profile is shifted to the right in the presence of surfactant (Figure 34).
Enoxaparin’s apparent molecular weight is overestimated in the absence of surfactant
and decreases in the presence of surfactant.

Proportion of Chains (%)

SEC-HPLC Profiles of Enoxaparin
100
No Surfactant

80

0.01% Tween 80
60

0.02% Tween 80

40

0.05% Tween 80

20
0
0

10000

20000

Apparent Molecular Weight (Da)

30000

Figure 34. SEC-HPLC chromatogram of enoxaparin showing SEC-HPLC conducted with
no surfactant and varying concentrations of Tween 80 in the mobile phase.
As with the previous polymers, no trend is observed that depends on the
concentration of the surfactant and the effect on apparent molecular weight appears to
be similar for all concentrations of surfactant (Table 8). The polydispersity index of
enoxaparin was greater when surfactant was used than when it was not (Table 8).
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Table 8. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of enoxaparin
MN
MW
Enoxaparin
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

7617
3000
5085
3369

±
±
±
±

302
253
571
331

(~10% error)

(~10% error)

7737
4213
6087
3967

9549
8332
9717
7072

1.23
1.99
1.59
1.78

The molecular weight distribution breakdown for enoxaparin changes in the
presence of surfactant following the same trend as CDS did: the increase in percent of
smaller molecular weight (less than 6000 Da) chains in the presence of surfactant (Figure
35). Only 8% of chains fall below 6000 Da when surfactant is absent, but this increases
to 60-80% the percent in the presence of surfactant. The percentage of medium chains
(6000-10000 Da) decreased from 39% in the absence of surfactant to ~16% in the
presence of surfactant. The trend was similar for CDS medium chains, which decreased
by almost half (Figure 31).
Because the FDA stipulates several requirements for the molecular weight
distribution pattern of enoxaparin between 2000 – 8000 Da, a breakdown of those
numbers was calculated in addition (Figure 36). The medium chains (2000 – 8000 Da)
vary only from 54% to 61%, or roughly half, of the enoxaparin sample tested.
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Figure 35. Molecular weight distribution of enoxaparin in the presence and absence of
different concentrations of surfactant used in the mobile phase for SEC-HPLC analysis

Figure 36. Smaller molecular weight distribution of enoxaparin in the presence and
absence of surfactant used in the mobile phase for SEC-HPLC analysis
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3.4.2.3 Discussion of CDS and Controls
Certain stipulations set out by regulatory bodies for control anticoagulants used in
our studies (heparin and enoxaparin) and the results we achieved are compared in Table
9. As mentioned in the introduction to heparin, the USP dictates several requirements for
manufacturers of pharmaceutical grade heparin. The heparin sodium for research we
used in the SEC-HPLC analysis only met two of these criteria (shown in green) when no
surfactant was present in the mobile phase (Table 9).
Heparin’s apparent molecular weight data was more accurate when compared
with literature values when measured with no surfactant than when measured with
surfactant. Enoxaparin was the opposite: apparent molecular weight data was more
accurate when measured with surfactant than when measured without surfactant. CDS
also exhibited opposite trends from heparin, similar to enoxaparin. Although CDS was
originally designed as a mimetic of heparin, its behavior in solution more closely mimics
that of the LMWH, enoxaparin, rather than that of heparin.
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Table 9. Controls heparin and enoxaparin calculated molecular weights from SECHPLC studies comparison with known parameters. Red text indicates the measurement
fell outside requirements; Green text represents satisfied requirements
Weight average
% > 24000
Ratio of chains
Heparin
molecular
Da
8000-16000 : 16000-24000
weight (MW)
< 20% of
15000 – 19000
Required by USP
≥ 1.0
sample
Da
Measured with:
No Surfactant
11.55
18267
0.27
0.01% Tween 80
33.26
27506
0.82
0.02% Tween 80
55.53
11488
0.48
0.05% Tween 80
28.81
22616
0.93
Peak average
%<
% 2000
%>
Polydispersity
Enoxaparin
molecular
2000
-8000
8000
weight (MP)
Da
Literature
1.1 – 1.5
4500
<10%
60-72% 22-36%
Measured with:
No Surfactant
1.23
7617
41.25
54.03
4.36
0.01% Tween 80
1.99
3000
30.65
57.92
11.68
0.02% Tween 80
1.59
5085
14.27
61.1
24.62
0.05% Tween 80
1.78
3369
33.43
55.69
11.13
3.4.3 Other Sulfated LMWLs (FDS and SDS)
Though FDS and SDS SEC-HPLC results are similar to that of CDS, a few
differences worth noting are mentioned below.
3.4.3.1 FDS
The average SEC-HPLC profile of FDS shifts to the right and changes in shape
from bimodal to unimodal with the addition of surfactant, similar to how CDS behaved
(Figure 37). FDS’s apparent molecular weight was 8338 Da when measured without
surfactant, but dropped ~25% when surfactant was present in the mobile phase (Table
10). The polydispersity increased ~30% once surfactant was added.
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Figure 37. SEC-HPLC chromatogram of FDS showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used
in the mobile phase.
Table 10. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of FDS. *MN and MW for 0.02%
and 0.05% Tween 80 were calculated solely from FDSBH rather than an average of FDSBH,
FDSMT, and FDSJT due to sampling error in the excluded samples.
MN
MW
FDS
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

8338
6080
7470
5641

±
±
±
±

871
663
828
161

(~10% error)

(~10% error)

8251
8857
6586*
6493*

11622
15464
17772*
15584*

1.41
1.75
2.37
2.32

The molecular weight distribution breakdown of FDS without surfactant consisted
of 41% small chains (< 6000 Da) that increased by ~20% in the presence of surfactant
(Figure 38). The percentage of medium chains (6000 – 10000 Da) was 31% when
surfactant was absent and decreased by more than half when surfactant was present.
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Figure 38. Molecular weight distribution of FDS in the presence and absence of different
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis

3.4.3.2 SDS
The average SEC-HPLC profile of SDS also shifts to the right and changes in
shape from bimodal to unimodal with the addition of surfactant, similar to how CDS and
FDS behaved (Figure 39). As with the others, the peak average molecular weight
decreased in the presence of surfactant, but even more drastically by ~60% for SDS
(Table 11). The number average molecular weight was also decreased in the presence
of surfactant, but the weight average molecular weight was higher when 0.02% Tween
80 was present. This anomalous increase and resultant very high polydispersity of more
than 3 is visible in the profile with a higher baseline than the other data acquired with
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surfactant (Figure 39). The larger numbers could be explained by the elevated baseline
which can change for experiments performed on different days as was the case here.
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Figure 39. SEC-HPLC chromatogram of SDS showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used
in the mobile phase.

Table 11. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of SDS.
MN
MW
SDS
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

7765
2282
4354
2716

±
±
±
±

228
623
162
170

(~10% error)

(~10% error)

6827
1892
3728
2270

8809
3294
12527
3760

1.29
1.74
3.36
1.66

SDS has lower molecular weight and shorter chains than CDS and SDS. This is
expected because sinapic acid, the starting monomer, has an additional methoxy
functional group in place of a hydrogen that is available on CDS/FDS to react and form
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the β-5 linkages. Because this hydrogen is not available on SDS, it cannot form β-5
linkages, and therefore is primarily made up of β-O-4 linkages. Sinapic acid is considered
to have lower polymerizability than caffeic and ferulic acid. Because of sinapic acid’s
inability to form β-5 linkages and low polymerizability, the resulting polymer SDS has
shorter chains and lower molecular weight than CDS and FDS.
The molecular weight distribution breakdown of SDS contained 44% small chains
(< 6000 Da) when no surfactant was present, but there number of small chains doubled
when surfactant was present (Figure 40). The percentage of medium chains (6000 –
10000 Da) was greatly decreased in the presence of surfactant than without surfactant.
A molecular weight distribution breakdown more representative of the smaller molecular
weight of SDS was calculated for all mobile phases containing surfactant (Figure 41).
The apparent molecular weight range of SDS when measured with no surfactant
was too large to present distribution less than 2000 Da and was not included.
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Figure 40. Molecular weight distribution of SDS in the presence and absence of different
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis

Figure 41. Smaller molecular weight distribution pattern more representative of SDS in
the presence and absence of different concentrations of surfactant used in the mobile
phase for SEC-HPLC analysis
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3.4.4 Unsulfated LMWLs: CD, FD, SD
Combining SEC-HPLC results of the unsulfated LMWLs with that of their sulfated
counterparts: CDS, FDS, and SDS gives us insight into the degree of sulfation of the
sulfated LMWLs. Because each sulfated LMWL was generated from the starting
unsulfated polymer, the molecular weight of the sulfated LMWL theoretically should be
increased by the weight of the number of sulfate groups introduced onto the polymer.
Therefore, subtracting the molecular weight of the unsulfated LMWL from its
corresponding sulfated LMWL and dividing the resulting difference by the molecular
weight of a sulfate group, will give us an estimate of the average number of sulfate groups
present on the polymer. To estimate the number of monomer units per polymer chain,
one can divide the molecular weight of the unsulfated LMWL by the molecular weight of
the starting monomer: caffeic, ferulic or sinapic acid. The number of sulfate groups can
then be divided by the number of monomer units to describe the average degree of
sulfation of the LMWL. A table of properties for the sulfated LMWLs calculated according
to the above method is provided in the conclusion of the SEC-HPLC section below.
3.4.4.1 CD
Although slightly less visible for CD, all three unsulfated LMWLs also demonstrated
the change from bimodal to unimodal profiles due to the addition of surfactant (Figure 42).
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Figure 42. SEC-HPLC chromatogram of CD showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used
in the mobile phase.
In addition, all unsulfated LMWLs shifted their profiles to the right when surfactant
was added and had lower peak average molecular weights (Table 12). Also, no trend
depending on the concentration of surfactant was observed and the effect of surfactant
on apparent molecular weight can be considered concertation independent. While the M P
and MN were decreased by about 50% for CD in the presence of surfactant, the MW
exhibited anomalous results with 0.02% Tween 80 and was increased from 9362 Da
without surfactant to 10025 Da at this concentration. This could be due to sampling error
or day to day variation in the baseline of the HPLC system.
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Table 12. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of CD.
MN
MW
CD
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

7487
3025
4077
3021

± 311
± 372
± 216
± 96

(~10% error)

(~10% error)

7376
3107
4612
3145

9362
6115
10025
6605

1.27
1.97
2.17
2.1

The polydispersity was increased by ~35% when surfactant was added, possibly
due to larger molecular weight species and aggregates being disrupted by the surfactant
and contributing additional chains to the overall sample.
The molecular weight distribution breakdown of CD revealed that when surfactant
was added, the proportion of small chains (< 6000 Da) increased from ~60% to ~80% of
the sample (Figure 43). The percent of medium (6000 – 10000 Da) and large (>10000
Da) chains decreased about 50% when surfactant was added.
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Figure 43. Molecular weight distribution of CD in the presence and absence of different
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis
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3.4.4.1 FD
The SEC-HPLC profiles of FD demonstrate similar trends as discussed for the
sulfated LMWLs and CD above (Figure 44).

Figure 44. SEC-HPLC chromatogram of FD showing bimodal distribution of the proportion
of chain lengths when SEC-HPLC is conducted with no surfactant and unimodal
distribution of chain lengths when varying concentrations of Tween 80 are used in the
mobile phase.
The weight average molecular weight of FD when measured with 0.02% Tween
80 also was subject to an anomalous increase over the MW measured with no surfactant,
as was seen with CD and the other polymers (Table 13). Because this anomaly occurs
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across several of the data gathered the days when 0.02% Tween 80 was being used, it
is likely an instrument related discrepancy. The molecular weight distribution breakdown
of FD was similar to results discussed with CD (Figure 45).
Table 13. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of FD.
MN
MW
FD
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

6805
2620
3596
2394

± 558
± 183
± 656
± 50

(~10% error)

(~10% error)

6547
2944
4423
2667

9756
5106
13588
7430

1.49
1.73
3.07
2.79

Figure 45. Molecular weight distribution of FD in the presence and absence of different
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis.
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3.4.4.1 SD
The SEC-HPLC profile of SD shows the most obvious bimodal distribution when
no surfactant is used in the mobile phase of all the LMWLs (Figure 46). Due to the
presence of only β-O-4 linkages discussed before for SDS, SD may be the LMWL most
subjected to hydrophobic interactions due to greater availability of the benzene rings in
the backbone to interact with one another. SD and SDS have enhanced flexibility than
the other LMWLs due to the absence of the bicyclic β-5 linkage. SD may be even more
likely to aggregate than SDS due to the absence of large and negatively charged sulfate
groups in SDS that would electrostatically repel one another. This could all serve to
explain the enhanced large molecular weight mode seen in the SD profile, which likely
represents aggregated smaller SD chains.

Figure 46.SEC-HPLC chromatogram of SD showing bimodal distribution of the proportion
of chain lengths when SEC-HPLC is conducted with no surfactant and unimodal
distribution of chain lengths when varying concentrations of Tween 80 are used in the
mobile phase.
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An opposite trend was observed with CD and FD, where their sulfated counterparts
CDS and FDS had higher calculated molecular weights, which could be logically
explained by the addition of sulfate groups. However, an alternative explanation for the
increased molecular weight of the sulfated LMWLs could be that the addition of sulfate
groups actually increases the molecules tendency to aggregate. This is because the
introduction of dual characteristics (hydrophobic backbone and negatively charged
functional groups) to the sulfated LMWLs may cause them to associate with themselves
in a manner similar to cell membranes or micelles, where hydrophobic moieties are
sequestered together away from water and hydrophilic parts arrange towards water.
Similar to the other LMWLs, the apparent MP and MN of SD was reduced by ~50%
when surfactant was used in the mobile phase and polydispersity was increased by ~40%
(Table 14). Once again the MW measured with 0.02% Tween 80 in the mobile phase was
anomalous and can be disregarded.

Table 14. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of SD.
MN
MW
SD
MP
Polydispersity
No surfactant
0.01% Tween 80
0.02% Tween 80
0.05% Tween 80

8849
4025
5745
4060

± 199
± 72
± 245
± 162

(~10% error)

(~10% error)

9264
4105
6975
4540

12614
6438
16331
8555

1.36
1.57
2.34
1.88

Similar to the trend seen with the other LMWLs, the molecular weight distribution
breakdown of SD showed the percent of small chains (< 6000 Da) increase by twice and
medium (6000-10000 Da) and large (>10000 Da) chains decrease by half (Figure 47).
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The molecular weight of the unsulfated LMWL, SD, at 8849 Da was higher than
the molecular weight for sulfated LMWL SDS of 7765 Da. This is unexpected because
the sulfated LMWL should have a larger average molecular weight than its unsulfated
precursor due to the weight of added sulfate groups. However, the batch of SD that the
SDS used in this work was originally synthesized from could have been different than the
SD sample used in the SEC-HPLC analysis. SDS could also have degraded in solution
during storage at a greater rate than the SD did, explaining why its molecular weight was
reduced.

Figure 47. Molecular weight distribution of SD in the presence and absence of different
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis
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3.4.5 Batch Variability – CDS and FDS
Chromatograms of all individual batches of CDS and FDS are available in
Appendix 1.
Batches of CDS had similar apparent peak average molecular weights when
measured without surfactant and when measured with 0.02% Tween 80, but batch
CDSMT1 had a greater MP when measured with 0.01% and 0.05% Tween 80 than the
other batches (Table 15). A possible explanation for this batch variability could be related
to stability of the polymer over time because the batches were synthesized several years
apart. Unfortunately, this explanation won’t work because CDS MT2 was the most recently
synthesized batch and therefore should have been subjected to less degradation
reactions over a shorter storage time, and could therefore logically have higher molecular
weight. Alternative reasons for this batch variability could be related to instrument or
sampling error or day to day variation in the experiments.
FDS batches had fairly similar peak average molecular weights for all mobile
phases except 0.05% Tween 80 (Table 15). The ~30k Da MP calculated for FDSMT and
FDSJT with 0.05% Tween 80 in the mobile phase is a sampling error of those batches and
can be disregarded as outliers.
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Table 15. Peak average molecular weight calculated from SEC-HPLC studies and
associated error for all mobile phases

Peak Average Molecular Weight
Polymer

Without
Surfactant

Tween 0.01
%

Tween 0.02
%

Tween 0.05 %

CDSMT1

9251 ± 249 7100 ± 598 5547 ± 334

5641

±

528

CDSMT2

9255 ±

4729 ± 275 5439 ± 473

4337

±

192

CDSBH

9013 ± 177 4916 ± 214 6175 ± 426

4471

±

117

FDSMT

8843 ± 392 6377 ± 291 8256 ± 415 30861 ± 1257

FDSJT

7464 ± 931 6546 ± 911 6713 ± 774 28897 ± 1253

FDSBH

8936 ± 241 5474 ± 372 6801 ± 360

19

4804

± 1453

Batch variability for CDS’s number average molecular weight was similar to that of
peak average molecular weight (Table 16). FDSMT and FDSJT were also subjected to
sampling error when 0.02% and 0.05% Tween 80 was used in the mobile phase, and the
over 10k Da MN averages should be disregarded.

Table 16. Number average molecular weight calculated from SEC-HPLC studies and
associated error for all mobile phases
Number Average Molecular Weight
Without
Polymer
Tween 0.01 % Tween 0.02 %
Tween 0.05 %
Surfactant
CDSMT1

10343 ±

183

7090

±

144

5785

±

354

6112

± 224

CDSMT2

10098 ±

76

5792

±

95

6644

± 1333

5292

± 101

CDSBH

9032

±

359

5506

±

72

5808

± 1107

4889

±

FDSMT

9327

±

884

7143

±

235 16912 ± 1528 19464 ± 110

FDSJT

9006

± 1059 6220

±

61

11707 ±

FDSBH

8827

±

±

97

5808

626

6203
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129

± 1107
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15200 ± 405
7641

± 259

Batch CDSMT1 had greater weight average molecular weight than the other two
batches of CDS across the board regardless of mobile phase (Table 17). FDSMT and
FDSJT had larger MW than FDSBH across the board regardless of mobile phase.
Table 17. Weight average molecular weight calculated from SEC-HPLC studies and
associated error for all mobile phases
Weight Average Molecular Weight
Without
Polymer
Tween 0.01 % Tween 0.02 % Tween 0.05 %
Surfactant
CDSMT1 12203 ± 137 10585 ± 800 16000 ± 43
9116 ± 216
CDSMT2

11524 ±

91

8566

± 632 14569 ± 3339

7885

± 106

CDSBH

10276 ±

470

8090

± 431 12335 ± 3149

7138

± 126

FDSMT

12462 ± 1512 10994 ±

FDSJT

12422 ± 1418 10608 ± 127 27234 ±

FDSBH

11354 ±

838

9383

94

±

62

32138 ± 1197 30210 ± 330
202

28154 ± 195

12335 ± 3149 14438 ± 937

The polydispersity for CDS batches, as well as FDS batches, did not vary
excessively amongst any of the mobile phases used (Table 18).
Table 18. Polydispersity index (Mw/Mn)

Polymer

Without
Surfactant

Tween 0.01 %

Tween 0.02 %

Tween 0.05 %

CDSMT1

1.18

1.49

2.77

1.49

CDSMT2

1.14

1.48

2.19

1.49

CDSBH

1.14

1.47

2.12

1.46

FDSMT

1.34

1.54

1.90

1.55

FDSJT

1.38

1.71

2.33

1.85

FDSBH

1.29

1.51

2.12

1.89

3.4.6 Alternative Surfactant: Triton X-100
Triton X-100 is another non-ionic surfactant used in addition to Tween 80 to see if
the effect of surfactant on apparent molecular weight was reproducible for multiple
83

surfactants. Tween 80 and Triton X-100 are both polydisperse, heterogeneous mixtures
themselves and their structures are provided in the Method Development section (Figure
26). Triton X-100 differs from Tween 80 notably by the presence of an aromatic benzene
ring its core instead of a tetrahydrofuran core characteristic of Tween 80. Because Triton
X-100 contains an aromatic moiety, it can engage in hydrophobic interaction with our
LMWL’s aromatic scaffold. Results for the sulfated LMWLs are below and chromatograms
for the unsulfated LMWLs and controls heparin/enoxaparin with Triton X-100 in the mobile
phase are in Appendix 2.
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Figure 48. SEC-HPLC chromatogram of CDS showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying surfactants are used in the mobile
phase.
The profile for CDS when analyzed with 0.02% Triton X-100 in the mobile phase
of the HPLC shifts to the left in comparison with the profile when no surfactant is used
(Figure 48). This is similar to what occurred with the surfactant Tween 80, and the same
concentration of 0.02% Tween 80 results are included here for direct comparison between
surfactants. Noticeably, the profile for 0.02% Triton X-100 shows the presence of high
molecular weight species on the right tail in greater quantity than when the same
concentration of Tween 80 is used. The Triton X-100 profile even exceeds the second
mode of high molecular weight species or aggregated chains seen in the profile acquired
when no surfactant was used. Because the higher molecular weight species are still
present and present in greater proportion when Triton x-100 is used compared with no
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surfactant, it is likely that Triton X-100 itself is interacting with CDS through plausible
hydrophobic interactions.
Table 19. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of CDS, including alternative
surfactant Triton X-100.

CDS

MP

MN

MW

(~10% error)

(~10% error)

8604
5513
7393

12242
14217
11598

No surfactant
9121 ± 170
0.02% Tween 80 5742 ± 512
0.02% Triton X-100 5845 ± 972

Polydispersity
1.42
2.58
1.57

The apparent peak average molecular weight of CDS decreased by ~35% from
9121 Da when measured without surfactant to ~5800 Da when either surfactant was
used in the mobile phase (Table 19).
The molecular weight distribution breakdown of Triton X-100 shows a 40%
increase from 33% of the sample consisting of large chains (> 10000 Da) when no
surfactant was used in the mobile phase compared with 53% of the sample being large
chains when Triton X-100 was used (Figure 49). This is in contrast to the trend seen with
the other surfactant, Tween 80, which had a reduction in the proportion of large chains
and an increase in the proportion of small chains. Triton X-100 may be effective at
breaking up aggregation amongst small and medium chains, but may become entangled
with large chains and aggregate with multiple chains of CDS, evidenced by the 40%
increase in the proportion of larger molecular weight species.

86

Figure 49. Molecular weight distribution of CDS achieved when SEC-HPLC is conducted
with no surfactant and the same concentration of two different surfactants in the mobile
phase.
The profile of FDS, when analyzed with Triton X-100 in the mobile phase,
anomalously shifted to the right instead of the left, which was the opposite trend seen
with the addition of surfactant for all polymers tested aside from heparin (Figure 50).
Polydispersity is also less at 1.32 when Triton X-100 is used in the mobile phase
compared to 1.41 when it is not.
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Figure 50. SEC-HPLC chromatogram of FDS showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying surfactants are used in the mobile
phase. Apparent molecular weight is most overestimated in the presence of Triton X-100
which contains an aromatic group.

Table 20. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of FDS, including alternative
surfactant Triton X-100. *MN and MW for 0.02% Tween 80 were calculated solely from
FDSBH rather than an average of FDSBH, FDSMT, and FDSJT due to sampling error in the
excluded samples.
MN
MW
FDS
MP
Polydispersity
No surfactant
8338 ± 871
0.02% Tween 80
7470 ± 828
0.02% Triton X-100 14200 ± 4806
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(~10% error)

(~10% error)

8251
6586*
13923

11622
17772*
18442

1.41
2.37
1.32

Two of the three FDS batches were subject to sampling error when 0.02% Tween
80 was used in the mobile phase, and it is likely that this illogical result is also due to
sampling error with FDS (Table 20). As an alternative explanation, Triton X-100 could be
aggregating with FDS through the same hydrophobic interactions possible with CDS
discussed above. Aggregation of large molecular weight chains of FDS and several
molecules of Triton X-100 could be characteristic of the increased MP, MN, and MW
calculated when this surfactant is used compared to when it is not (Table 20).

Figure 51. Molecular weight distribution of FDS achieved when SEC-HPLC is conducted
with no surfactant and the same concentration of two different surfactants in the mobile
phase.
The molecular weight breakdown of FDS when Triton X-100 was used in the
mobile phase was similar to that of CDS (Figure 51). The percent of small chains (< 6000
Da) dropped from 41% of the sample when measured with no surfactant to 25% when
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Triton X-100 was used in the mobile phase. Also, the percent of medium chains (6000 –
10000 Da) dropped from 31% of the sample when measured with no surfactant to 20%
when Triton X-100 was used in the mobile phase. However, the percent of large chains
(> 10000 Da) followed the opposite trend and was increased from 28% when no
surfactant was used to 52% when Triton X-100 was used in the mobile phase.
The change in the SEC-HPLC profile of SDS due to the addition of Triton X-100 in
the mobile phase was once again similar to that of CDS (Figure 52). The MP, MN, and MW
calculated when Triton X-100 was used in the mobile phase were decreased 30-50%
compared to when no surfactant was present (Table 21).

Proportion of Chains (%)

Average SEC-HPLC Profiles of SDS
100
80
60
40

SDS no surfactant

20

SDS 0.02% Triton

SDS 0.02% Tween

0
0

10000

20000

30000

Apparent Molecular Weight (Da)

Figure 52. SEC-HPLC chromatogram of SDS showing bimodal distribution of the
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and
unimodal distribution of chain lengths when varying surfactants are used in the mobile
phase.
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Table 21. Peak average molecular weight (MP), Number average molecular weight (MN),
weight average molecular weight (MW), and polydispersity of SDS, including alternative
surfactant Triton X-100
MN
MW
SDS
MP
Polydispersity
(~10% error)

(~10% error)

6827
3728
4323

8809
12527
6834

No surfactant
7765 ± 228
0.02% Tween 80
4354 ± 162
0.02% Triton X-100 3738 ± 104
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1.29
3.36
1.58

Figure 53. Molecular weight distribution of SDS achieved when SEC-HPLC is conducted
with no surfactant and the same concentration of two different surfactants in the mobile
phase
The molecular weight distribution breakdown of SDS revealed an increase in the
percentage of small chains (< 6000 Da) from 44% of the sample when no surfactant was
used to 91% when Triton X-100 was used in the mobile phase (Figure 53). Because of
SDS’s smaller molecular weight distribution, a breakdown more representative of SDS
was also calculated (Figure 54). However, the distribution spread from < 1000 to > 2000
Da was not feasible to calculate for the SDS data acquired with no surfactant, so only the
two surfactants are compared. While the percent of medium chains (1000 – 2000 Da) is
similar (~18%) for both surfactants, there were less small (< 1000 Da) chains (1% vs
30%) and more large (> 2000 Da) chains (82% vs 55%) when Triton X-100 was used in
that mobile phase than when 0.02% Tween 80 was used.
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Figure 54. Smaller molecular weight distribution of SDS achieved when SEC-HPLC is
conducted with same concentration of two different surfactants in the mobile phase
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3.5 SEC-HPLC of LMWLs: Conclusions
SEC-HPLC analysis of LMWLs and control polymers revealed that although
LMWLs were originally designed as heparin mimetics, in solution they behave more like
enoxaparin than heparin. The molecular weights of LMWLs and enoxaparin were
overestimated when no surfactant was used in the mobile phase of the HPLC and
decreased when surfactant was added. This trend contrasted with heparin, which had
greater average molecular weight measurements when surfactant was used in the mobile
phase compared to when surfactant was not present.
Table 22. Physical properties of sulfated LMWLs and control polymers. Size was obtained
by dividing the polymer average molecular weight by the weight of monomer unit. Number
of sulfate groups was obtained by combining sulfated and unsulfated LMWL SEC-HPLC
results. Peak average molecular weights were calculated from SEC-HPLC studies with
0.02% Tween 80 in the mobile phase. Because SD had higher molecular weight than
SDS, data from literature was used when calculations could not be performed.
Range of
Weight
Sulfate
Peak average
oligomer
average
groups per
molecular
chain length
oligomer size
monomer
weight (Da)
CDS
17-47
44
0.4
5742
FDS
12-50
46
0.5
7470
22
22
22
SDS
4-11
14.4
0.38
4354
Enoxaparin
6-2722
12.622
1.1422
380022
Heparin
10-8022
~4022
1.2822
1300022

The molecular weight of CDS is likely 1.5-2 times higher than the previously reported
value from elemental analysis of sulfated LMWLs and extrapolated calculations from gel
permeation chromatography (GPC) HPLC analysis of unsulfated LMWLs (Table 22). The
higher molecular weight of ~6000 Da is a better estimation of the average size of CDS
than the previously reported value of 3320 Da because the sulfated LMWLs were directly
measured on SEC-HPLC.
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The use of surfactant in the mobile phase of the HPLC likely disrupts LMWLs tendency
to aggregate due to hydrophobic interactions. Whether 0.01% or 0.05% Tween 80 was
used, the effect on the apparent molecular weight is relatively similar, therefore the effect
surfactant is concentration independent. Including Tween 80 in the mobile phase of the
HPLC at a concentration of as low as 0.01% is likely adequate to disrupt aggregates of
LMWLs. Even though the surfactant is likely disrupting some high molecular weight
species, it cannot account for all of the high molecular weight species, indicating the
presence of some long, heavy chains in the sample. The SEC-HPLC profiles of LMWLs
change from bimodal when no surfactant is used in the mobile phase to unimodal once
surfactant is added. The rightmost mode in the bimodal profile likely represents
aggregated high molecular weight chains. The proportion of high molecular weight chains
decreases by a factor of 2 in presence of surfactant in the LMWL CDS.
FDS and SDS behaved with similar trends as CDS, although there are likely a few
chains in FDS that are longer and bigger than in CDS. SDS has average molecular weight
values less than that of CDS and FDS. This is expected because sinapic acid, the starting
monomer of the SDS polymer, can’t form B-5 linkages due to substitutions with more
methoxy groups than the other cinnamic acid derivatives, caffeic and ferulic acid. Sinapic
acid does not have an available hydrogen to generate the appropriate radical for β-5
linkage formation, and therefore exhibits less polymerizability than caffeic and ferulic acid.
SDS is less polydisperse than CDS and FDS, as expected due to the lower degree of
polymerizability and more uniform, primarily β-O-4 linkage pattern.
The use of an alternative surfactant, Triton X-100, in the mobile phase of the HPLC
resulted in anomalous molecular weight distribution profiles. Triton X-100 contains an
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aromatic ring that could possibly engage in π-π stacking and other hydrophobic
interactions with aromatic scaffold of LMWLs. The possible hydrophobic interactions with
this surfactant in the mobile phase of the HPLC could explain the anomalous trend in
molecular weight distribution profiles of the LMWLs.
3.6 Molecular Dynamics Simulations
Theoretical methods are becoming more sophisticated and computational
chemistry is being seen as an increasingly useful tool to medicinal chemists. 67 Molecular
dynamics (MD) is the science of simulating the motions of a system of particles and gives
the fluctuations in relative positions of atoms as a function of time.68 Small, rigid molecules
may have only one conformation that contributes to the properties of a system, whereas
larger more flexible molecules (like polymers) have several conformations.67 All atoms in
the molecular system have a vector direction, velocity, and mass; and force is exerted by
the atoms on one another.69
MD simulations give a trajectory of molecule conformations over time of a system
by integrating Newton’s equations of motion.69 Computational molecular dynamics (MD)
simulations may be well suited to the study of polymers because they allow for sampling
of the conformational space that polymers can occupy. Polymers are not rigid entities,
rather they are highly flexible and can adopt a number of conformations in solution and
interact not only with themselves and other polymer chains, but with the solvent molecules
surrounding them as well. The conformational diversity of polymers has a significant
impact on their physicochemical and biological properties, so modeling the behavior of
LMWLs with MD simulations can give important insight to understanding their nature in
solution.70
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Details of molecular structures and interactions can be predicted by using quantum
mechanics, but computational costs can be extremely high even for small molecules –
polymers are even more difficult.71 MD simulations are advantageous because of their
relatively low cost, but appropriate force fields and parameters are needed to conduct
them. Force fields consist of equations chosen to model potential energy, but there is no
unique solution for the optimal set of functions and parameters. 71 The goal of a force field
is to provide good quality geometries and relative energies for a myriad of organic
molecules through energy minimization.72 Descriptions of atoms, bonds, and angles are
parameters that need to be available in the force field that is an appropriate model of a
system.73
It would be difficult and computationally expensive to define parameters to be an
appropriate model of CDS using the force fields CHARMM or Amber due to the amount
of quantum mechanics calculations needed for polymers. CHARMM and Amber were
developed in response to the need for modeling in specific areas and can accurately
describe narrow classes of compounds.72 However, a major assumption in attempting to
model CDS is that any one structure is an accurate representation of the polydisperse,
heterogeneous mixture that CDS exists as in reality.
Because CDS molecules are not structurally defined, it is hard to define suitable
parameters to model CDS accurately. The Tripos force field was chosen for MD
simulations of CDS because it has been shown to produce molecular geometries close
to the crystal structure of a diverse selection of molecules.72 Although the Tripos force
field might not be ideal, we chose to use Tripos because it has been successful previously
to describe a large variety of molecules and is highly generalizable. 72
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In molecular dynamics simulations, only a small fraction of the total conformational
space accessible to the polymer is sampled in a time period of 10 – 100 picoseconds.69
The limited sampling of the conformational space available for a molecular system is a
major source of error in simulations of macromolecules.69
3.6.1 Introduction: SEC-HPLC Background
The sulfated dehydropolymer of caffeic acid (CDS) is a synthetic polymer designed
as a mimetic of the well-known anticoagulant unfractionated heparin (UFH). CDS has
shown good activity as an anticoagulant and anti-emphysema agent.5-9 Although
developed as a heparin mimetic, it has a dramatically different scaffold than UFH. Where
CDS contains an aromatic, hydrophobic backbone, heparin has a polysaccharide
backbone. To investigate whether different backbones induce different physicochemical
properties, we performed size exclusion chromatography (SEC) of CDS and UFH in the
presence and absence of non-ionic surfactants. While the molecular weight of CDS was
determined to be closer to the reported literature value in the presence of surfactant,
UFH’s molecular weight was over estimated.
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Figure 55. Conflicting trend in behavior of apparent molecular weight from SEC-HPLC
studies between A) CDS and B) Heparin with and without the presence of Tween 80 in
the mobile phase

Figure 56. A comparison of heparin and CDS showing opposite trends of molecular
weight in the presence and absence of surfactant
The peak average molecular weight of CDS was determined from SEC-HPLC
studies to be overestimated from the reported literature value of 3320 Da by 2.74 times
when no surfactant was present, but only 1.65 times on average in the presence of
surfactants (Figure 55). The peak average molecular weight of heparin followed an
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opposite trend in that it was overestimated from the literature value of 13000 Da by 1.56
times in the absence of surfactant, but by 2.23 times in the presence of 0.02% Tween 80
(Figure 56). We hypothesized that the hydrophobicity of CDS was likely to induce
aggregation in aqueous solution in the absence of a surfactant (Figure 57). In contrast,
the hydrophilicity of heparin was likely to induce aggregation in the presence of a
surfactant. To support this hypothesis, molecular dynamics (MD) simulations were
performed using explicit solvation in Sybyl to model the polymers with and without
surfactant.
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Figure 57. Concept of aggregation and rational for addition of surfactant to mobile phase
of SEC-HPLC
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3.6.2 Methods
The polymers heparin and CDS were modeled with approximate structures using
the pentasaccharide sequence to represent heparin and a 7-monomer unit long chain of
CDS with 2 sulfate groups (Figure 58). Tween 80 was modeled with even length chains,
even though in reality Tween 80 itself is also a heterogeneous mixture. The assumption
that the selected structures used in modeling are representative of all the possible
structures in the sample is a major limitation, as far greater size chains may behave
entirely different than the one structure used.
After molecule files were created for heparin, CDS, and Tween 80 alone, heparin
and Tween 80 were merged together as well as CDS and Tween 80 for a total of five
separate files. Molecules were energy minimized and then solvated before being energy
minimized again. Charged sulfate groups were balanced with positively charged sodium
counter ions (8 in heparin and 2 in CDS) in all simulations to ensure the overall charge of
the system was zero.
The simulation was run with Boltzmann initial velocities at 300 K using the Tripos
force field and Gasteiger-Huckel charges with periodic boundary conditions applied and
a dielectric function of distance. Sybyl outputs energy of the system after MD runs are
completed and the changes in interaction energies (ΔG) can be compared for heparin
and CDS with and without surfactant. Because aggregation is a favored energetic state
due to the contribution of increased entropy of the system overall due to displacement of
water molecules upon aggregation, it would be expected that an aggregate would have a
lower energy calculation than non-aggregated species. A surfactant that serves to break
up aggregation of polymer chains would have favorable (lower energy) interactions with
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the polymer. We therefore hypothesize that the change in interaction energy for CDS and
Tween 80 will be more favorable than the change in interaction energy for heparin and
Tween 80.

Figure 58. The structures of heparin, CDS, and Tween 80 used in MD simulations
selected as the best representation the polydisperse, heterogeneous mixtures
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MD simulations were performed using explicit solvation in Sybyl to model the
polymers with and without surfactant. Before the production run, two equilibration runs
were completed to ensure the system was at equilibrium. The first equilibration run was
an isothermal-isobaric run where the amount of substance (N), pressure (P), and
temperature (T) are conserved (NPT). The second equilibration run required the amount
of substance, volume (V), and temperature to be held constant (NVT). Each equilibration
was run with Boltzmann initial velocities at 300 K using the Tripos force field and
Gasteiger-Huckel charges with periodic boundary conditions applied and a dielectric
function of distance for 1000 iterations. Once the volume and pressure had reached
equilibrium, the final production NVT run could begin with the same parameters but run
for 100,000 iterations. The changes in interaction energies (ΔG) were calculated and
compared for heparin and CDS with and without surfactant from the following equation:
ΔGinteraction = ΔG(polymer + Tween 80) – (ΔGpolymer + ΔGTween 80)
3.6.3 First set of MD simulations - Results
For the first round of MD simulations, solvation was achieved by surrounding
molecules with 20 shells of water using explicit solvation in Sybyl and molecular
silverware. This resulted in water boxes around each molecule or molecule pair of
different sizes (Figure 59). Because we are comparing the energies calculated from the
entire system, the differing number of water molecules in each system are contributing a
varying energy to the system. To account for the effect of differing number of water
molecules in each box, an attempt to normalize the resulting data for comparison was
necessary by dividing calculated energy values by the number of heavy atoms in each
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box. A modified equation reflecting the energy values per heavy atoms was then utilized
to calculate the interaction energy:

ΔG

interaction

heavy atom

=

ΔGcomplex
Wt. of Heavy
Atoms

ΔGpolymer

-

+

ΔGTween

Wt. of Heavy
Atoms

Wt. of Heavy
Atoms

Number of Water Molecules in Box
15508

5715

Heparin

11658

11978

Tween

CDS + Tween

7144

CDS

Heparin +
Tween

Figure 59. Sizes of water boxes used in first set of MD simulations

The equilibration runs were successful in ensuring that the system was at
equilibrium and the pressure and temperature had stabilized. Example graphs of pressure
and temperature for the CDS water box at equilibrium are provided (Figure 60).
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Figure 60. Results after equilibration runs for CDS in a water box

The average potiential, kinetic, and total energy for a all five systems once they
had reached equilibrium for the first set of MD production runs is reported below (Table
23).
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Average Total
Energy(kcal/mol)

St. Dev.

Average Temp. (K)

Constant Density (g/mL)

St. Dev.

3

“Constant” Volume (Å )

Average Kinetic
Energy(kcal/mol)

-8917

69

15034

76

6117

9

292 1 27915 198 128500 1.35

CDS

-10646

63

18692

67

8046

11

290 1 27007 100 161752 1.34

TWEEN

-16870

86

30471

73

13601

19 291 1 28728 114 260182 1.35

CDS
-17687
+ TWEEN

65

31481

59

13794

18 292 1 27581 107 270214 1.34

HEPARIN
+
-23343
TWEEN

89

40683

78

17339

14 292 1 27210

St. Dev.

St. Dev.

HEPARIN

St. Dev.

Average Potential
Energy (kcal/mol)

Average Pressure (atm)

Table 23. Results from the first set of MD simulations

67

348943 1.34

Because of the differing number of water molecules in each box, adjusted
calculations are also provided (Table 24).
Table 24. Per weight of heavy atom energies calculated from the first set of MD

Heparin
CDS
Tween
CDS + Tween
Heparin + Tween
simulations

Average Total Energy
(kcal/mol)
6117
8046
13601
13794
17339

Average Energy Per Weight of
Heavy Atoms
0.0658
0.0700
0.0724
0.0712
0.0691

The ΔGinteraction per heavy atom for CDS and Tween 80 was -0.0711 kcal/mol/
heavy atom, lower (more negative = more favorable) than the ΔGinteraction per heavy
atom for heparin and Tween 80 of -0.0691 kcal/mol/ heavy atom. Although these values
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may be close enough to one another to call into question the statistical significance of
the difference, they are weighed per heavy atom. This result is in line with what we
expected from our hypothesis that Tween 80 and CDS interact more favorably than
Tween 80 and heparin.
3.6.4 Second set of uniform box size MD simulations
To eliminate the additional step of calculating the energy per heavy atom and to
minimize the associated potential for increased error, a second set of MD simulations was
performed in water boxes of the same size. The largest water box from the first set of
simulations contained heparin and Tween 80 along with 15,508 molecules of water and
was ~80 Å in diameter. Therefore, a water box of ~80 Å in diameter was created through
explicit solvation in Sybyl using molecular silverware. The number of heavy atoms in
heparin, CDS, and Tween 80 was used to delete the same number of water molecules
from each box before merging the molecule or molecule pair into the box in effort to keep
the density of all boxes the same. Boxes were then energy minimized and equilibrated as
was done in the first set of simulations. The same method and dynamics parameters were
used for the second set of MD simulations as discussed above.
The second set of MD simulations revealed that the interaction energy of CDS
and Tween 80 (ΔG = -28,887 ± -664 cal/mol) was slightly more favorable than that of
heparin and the surfactant (ΔG = -28,070 ± -952 cal/mol), but the difference was not
statistically significant (Table 25). However, the results may still support our hypothesis
and showed the same trend seen for the first set of MD simulations.
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Table 25. Results from the second set of MD simulations

A third set of MD simulations was planned by introducing a second molecule of
each polymer to better model aggregation between two chains of polymer rather than the
interaction of the surfactant with one molecule of polymer. Four boxes of the same size
that consisted of two molecules of heparin, two molecules of heparin with Tween 80, two
molecules of CDS, and two molecules of CDS with Tween 80 were created. From MD
simulations, we could calculate the interaction energies of two polymer chains with each
other, as a model of a polymer aggregate, and compare it with the change interaction
energy of that aggregate model when Tween 80 is present. Unfortunately, the size of the
water box necessary to fully solvate the system when three molecules are present (2
molecules of polymer and 1 molecule of Tween 80) was too large for Sybyl to run
dynamics simulations and violated the periodic boundary conditions.3.7 MD
Simulations: Conclusions
Preliminary results showed that the interaction energy of CDS and the surfactant,
Tween 80, was more favorable than that of UFH and Tween 80. A subsequent improved
experiment with water boxes of the same size confirmed this result and supported our
hypothesis. Aggregation is a favorable interaction (lower energy) due to the contribution
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of increased entropy of the system overall due to displacement of water molecules upon
formation of the aggregate. A surfactant that serves to break up aggregation of polymer
chains should have favorable (lower energy) interactions with the polymer. While both
CDS and heparin had favorable interactions with Tween 80, represented by the negative
change in interaction energies calculated from MD simulations, CDS had slightly more
negative, therefore more favored interactions with Tween 80.
Although developed as a heparin mimetic, it has a dramatically different scaffold
than heparin. Where CDS contains an aromatic, hydrophobic backbone, heparin has a
polysaccharide backbone. While the molecular weight of CDS was determined from SECHPLC studies to be closer to the reported literature value in the presence of surfactant,
heparin’s molecular weight was over estimated. This supports our hypothesis that the
hydrophobicity of CDS likely induces chemical aggregation in aqueous solution in the
absence of a surfactant. In contrast, the hydrophilicity of heparin likely induces physical
aggregation in the presence of a surfactant. The combination of MD results with those
from SEC-HPLC suggest that although CDS functions as a biological mimetic of heparin,
it is not a chemical mimetic and behaves differently in solution due to the two diverse
scaffolds.
MD is a possible way to model polymers behavior in solution, but theoretical
models require some assumptions and are subject to several limitations. Our first
assumption is that the structures we used in MD simulations are adequate
representations of the polydisperse, heterogeneous polymer mixtures. This is a major
assumption, because LMWLs and heparin do not have a completely defined structure
and how the polymer really exists in solution is unknown. Other limitations of this work
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include whether sampling was adequate over the time of the MD run, which is also
unknown. MD was a useful tool to learn more about polymers behavior in solution and
help explain the contrasting trend of molecular weight estimation in the presence and
absence of surfactants seen from SEC-HPLC studies. Many challenges exist with the
development of appropriate parameters to describe sulfated compounds and future work
to establish the validity of modeling polymer aggregation is needed.
4. Physicochemical Characterization of LMWLs
4.1 Introduction
While the previous chapter discussed efforts to characterize the structure of
sulfated LMWLs, the following chapter is a summation of measured physicochemical
properties of the same LMWLs used in SEC-HPLC studies. Characterization of
physicochemical properties, in addition to structural characterization, is another important
part of the information that has to be established in developing polymers as drugs. In an
attempt to estimate the hydrophobicity of sulfated LMWLs, we measured the octanolwater distribution coefficient of the library. Elemental analysis results provided us with the
amount of carbon, hydrogen, and sulfur content of two batches of the sulfated LMWL
CDS. Studies of various linkage patterns, degrees of sulfation, and extent of
decarboxylation revealed structures of CDS that matched closely with the elemental
analysis results and are the best representation of the structure of CDS described to date.
4.2 Octanol-water distribution coefficient (log D)
The octanol-water distribution coefficient (log D) is a measurement of a molecules
concentration ratio between two immiscible solvents at equilibrium. Log D can give an
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estimate of a molecules hydrophobicity/hydrophilicity and aid in our prediction of its
tendency dispersed in aqueous or organic solution as well as its likelihood to penetrate
lipophilic cell membranes. A drug’s ability to cross cell membranes is usually thought to
be limited when molecular weight surpasses 500 Da, but the sulfated LMWLs synthesized
in our lab have shown ability to get into cells and have a predicted molecular weight above
3000 Da. The aromatic nature of the backbone of sulfated LMWLs may be imparting an
overall hydrophobic character to the polymers, allowing them to snake through cell
membranes despite their large size and negative sulfate and carboxylic acid functional
groups.
To further characterize the physicochemical properties of LMWLs, log D was
measured for a handful of related control molecules, the unsulfated polymers (CD, FD,
SD) and the sulfated polymers (CDS, FDS, SDS). Control compounds chosen include the
monomer of each polymer in our LMWL library: caffeic acid (CA), ferulic acid (FA), and
sinapic acid (SA). Also chosen were acetylsalicyclic acid (ASA), salicylaldehyde (S), and
p-toluic acid (PT) due to their benzene core and carboxylic acid or hydroxyl functional
groups that are also present in LMWLs. Finally, p-toulenesulfonic acid (PTS) and 5sulfosalicylic acid (5SS) were also used as controls due to their benzene core and sulfate
functional groups, which are important modifications on the sulfated LMWLs. Chemical
structures and relevant literature values related to estimates of hydrophobicity are
provided for the controls (Table 26).

110

Table 26. Literature search results for various physicochemical properties of control compounds tested on our Log D
measurement system. (Abbreviations) for control compounds used in results figures.
Name

Caffeic Acid
(CA)

Structure

Log Kow

1.35 ± 0.0474

Ferulic Acid
(FA)
Sinapic Acid
(SA)
Acetylsalicylic Acid
(ASA)

-1.2 (pH 7.4,
phosphate buffer)81

Salicylaldehyde
(S)

1.65 (pH 5.6,
phosphate buffer)83

p-toluic Acid
(PT)

2.3685

p-toluenesulfonic
Acid
(PTS)

Estimated Log P

1.15±0.4775
1.58±0.4976
1.18±0.4777
1.42±0.4775
1.62±0.4976
1.70±0.4877
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Molar Absorption
Coefficient (ɛ)
(L mol-1 cm-1)

77.76
81.0074

1480078

66.76

1660079

1.29±0.4775
1.36±0.4976
1.83±0.5677

75.99

1780080

1.18±0.4775
1.24±0.4976
0.96±0.4877

63.6

110082

57.53

12000
(255nm)84

37.3

12598
(252nm)86

54.37

351
(262nm)87

111.9

31600
(292nm)88

1.20±0.4775
1.46±0.4976
0.83±0.3177
2.08±0.4775
2.21±0.4976
1.64±0.2877
1.68±0.4775
1.90±0.4976
0.96±1.4377
0.36±0.4775
0.85±0.4976
-0.49±1.6777

5-sulfosalicylic Acid
(5SS)

tPSA

4.2.1 Log D Measurement Methods
Molar absorption coefficients (ɛ) were established for our system by analyzing four
known concentrations (1, 5, 10, and 20uM) of control compounds at their λmax and
establishing calibration curves (Figure 61). Similarly, the molar absorption coefficients for
our library of polymers was measured on our system and used in calculations to
determine log D (Figure 62).
Log D measurements were taken at room temperature from 1.5mL screw-cap
glass vials that contained 500uL aqueous buffer (20mM sodium phosphate pH 7.4) and
500uL 1-octanol. Each compound was added by taking 10uL of 5mM stock solutions and
pipetting into the interface of the solvents. Vials were shaken vigorously for 2 minutes and
left on inversion table overnight. Vials were allowed to equilibrate for 72 hours on the
bench without shaking to minimize the effect of micro-droplets of octanol being dispersed
in the aqueous buffer. Preliminary experiments conducted over six days revealed that log
D measurements did not change significantly after 24 hours of equilibration time,
providing support for our use of 72 hours being more than adequate to achieve full
equilibration. After equilibration was ensured, 5uL samples of the aqueous buffer layer
were withdrawn and diluted to 100uL for analysis on the UV-spectrometer and
absorbance was recorded for each compounds’ λmax. Concentration in the 1cm cuvette
was calculated using the molar absorption coefficient measured on our system for each
compound and the Beer-Lambert law:
A = ɛ b [C]
where A is absorbance, ɛ is the molar absorption coefficient, b is the path length through
the cuvette, and [C] is the concentration. The concentration in the log D measurement
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vial was then back-calculated from the cuvette concentration and the ratio of
concentration between octanol:water (log D) was determined using the known
concentration of compound originally added to the vial.
4.2.2 Results and Discussion
Results for the molar absorption coefficients of control compounds were compared
with values found in the literature, although information on the methods of measurement
of literature values were not always included with the source. Molar absorption
coefficients may differ based on the buffer in which they are dissolved or the wavelength
at which they are measured, so direct comparison of our values with literature values may
not be generalizable. However, the control compounds CA, FA, SA, S, and PTS had
relatively similar measured molar absorption coefficients to the literature values, whereas
ASA, 5SS, and PT did not agree well (Figure 63).63-65,67,69-71,73

Absorbance of Known Concentrations of Controls
Absorbance at λmax

0.25

CA y = 0.01x + 0.0067

0.2

0.15

FA

y = 0.0097x + 0.0038

SA

y = 0.0105x + 0.0021

ASA y = 0.0059x + 0.0053
S

0.1

y = 0.0075x - 0.001

5SS y = 0.0091x + 0.0014
0.05

PT y = 0.0085x + 0.0005
PTS y = 0.0097x + 0.0016

0
0

5

10

15

20

Concentration (uM)
Figure 61. Known concentrations of control molecules analyzed on our system to
calculate molar absorption coefficients needed for log D calculations
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Molar Absorption Coefficient
(M-1cm-1)

Molar Absorption Coefficients of Controls

Figure 63. Comparison of molar absorption coefficients found in the literature
and measured on our system for control compounds

Absorbance of Known Concentrations of Library

Figure 62. Known concentrations of library molecules analyzed on our system to
calculate molar absorption coefficients needed for log P calculations
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Molar absorption coefficients for library compounds were also measured. Heparin
and enoxaparin were included in the analysis, but defied the Beer-Lambert principle of
concentration being directly proportional to absorbance and were not tested in log D
experiments (Figure 62).
Preliminary experiments were conducted over an extended period to determine
how long compounds took to equilibrate between organic and aqueous phases in the log
D measurement vial. The log D measurements after 24 hours were averaged together
and did not have large standard deviation from the average for the control compounds
tested, with the exception of p-toluenesulfonic acid which had large error in

D

measurements regardless of time of measurement (Figure 64).

Figure 64. Log D measurements of control compounds conducted over six days and
averaged measurements after 24 hours
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Average measured log D values of the control compounds from three subsequent
separate experiments were compared with literature values as well as with calculated log
P (C log P) values determined by predictive computer software (Figure 65). Compounds
CA, SA, ASA, and S were found to be in good agreement with literature values, whereas
FA, 5SS, PT, and PTS were not in such good agreement. Based on the disagreement of
both sulfated control compounds with literature values, our log D measurement method
may not be valid for similar compounds. However, because monomers and polymers are
known to behave differently and because of the good agreement of half the control
compounds and two of the monomers of LMWLs with literature log D values, we continued
with the method for testing the library compounds.

Literature Log P and Measured Log D of Controls
2.5

Log P or Log D

2

1.5

1

0.5

0

CA

FA

SA

Literature Log P

ASA

S

5SS

PT

PTS

Average Measured Log D

Figure 65. Control molecules average measured log D from three trials compared with
Log P literature values
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Table 27. Measured molar absorption coefficients and Log D values for control
compounds
Molar Absorption
Coefficient (ɛ)
(M-1cm-1)

Log D

Caffeic Acid

12138±2701
(282nm)

0.916±0.089

Ferulic Acid

11113±1982
(282nm)

0.761±0.065

Sinapic Acid

10600±663
(282nm)

0.793±0.148

Acetylsalicylic Acid

7600±2285
(220nm)

0.494±0.019

Salicylaldehyde

7438±492
(256nm)

1.265±0.134

5-sulfosalicylic Acid

9463±423
(236nm)

0.929±0.089

p-toluenesulfonic
Acid

10338±1109
(236nm)

0.757±0.168

p-toluic Acid

8650±238
(222nm)

0.753±0.036

Name

Structure

Molar absorption coefficient values and measured average log D values of control
compounds are summarized in Table 27.
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Molar absorption coefficient values and measured average log D values of library
compounds are presented below (Table 28) (Figure 66). Three batches each of FDS and
CDS were compared and found to show minimal batch variability in measured average
molar absorption coefficient: 71301 ± 12480 L mol-1 cm-1 (CDS); 95629 ± 15457 L mol-1
cm-1 (FDS) and log D: 0.96 ± 0.09 (CDS) and 0.96 ± 0.06 (FDS).
Table 28. Measured molar absorption coefficients and log D values of library compounds,
including three batches each of CDS and FDS averaged from three trials.
Molar Absorption Coefficient (ɛ)
Name
Log D
L mol-1 cm-1
CDSMT1
74283 ± 10786
1.06 ± 0.11
CDSMT2
57600 ± 10958
0.87 ± 0.09
CDSBH
82021 ± 7341
0.96 ± 0.09
FDSMT
102650 ± 22495
0.93 ± 0.09
FDSJT
77908 ± 14600
1.04 ± 0.1
FDSBH
106329 ± 19024
0.93 ± 0.09
SDS
107396 ± 60358
1.11 ± 0.11
CD
74563 ± 3018
0.8 ± 0.08
FD
110288 ± 6417
1.06 ± 0.11
SD
45329 ± 7699
0.88 ± 0.09

Distribution Coefficients of LMWLs

Log D

1.2
0.8
0.4
0

CDS

CD

SDS

SD

FDS

FD

Figure 66. Average measured log D values of LMWL library, showing sulfated (darker
shade) and unsulfated polymers (lighter shade) grouped by colors
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Average Log D values for sulfated and unsulfated LMWL are compared in Figure
66. In the case of CDS and SDS, the corresponding unsulfated LMWL (CD and SD) had
lower log D values compared with their sulfated counterpart. This is an interesting result
because one would expect a sulfated polymer with additional negative charges to be more
hydrophilic than its unsulfated precursor. This result indicates the importance of
recognizing that functional groups and overall charge are not necessarily the largest
contributor to the molecules overall character and behavior in solution. In the case of
FDS, the unsulfated precursor FD had a higher log D than FDS, which was the opposite
trend seen in the other two LMWLs. This could possibly be accounted for by the
observation early on from the control compounds where the FDS precursor, FA, had a
measured log D value on our system that was not in good agreement with the literature
value, whereas there was better agreement for both other LMWL precursors CA and SA.
4.2.3 Conclusions
For LMWLs that contain a number of negatively charged functional groups, it may
appear at first that these molecules would be very hydrophilic. However, results from log
D measurement indicate the library of LMWLs have log D around 1. Molecules with log D
values of close to 1 are approximately 10 times more concentrated in the organic phase
than the aqueous phase. Although the molecules contain charges, their aromatic
backbone imparts overall hydrophobic character to the molecules.
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4.3 Elemental Analysis
4.3.1 Introduction
Elemental analysis is a destructive process that reveals the elemental makeup of
a sample. We sent samples of two batches of CDS (CDSMT1 and CDSMT2) to Atlantic
Microlab, Inc. to be analyzed for carbon, hydrogen, nitrogen, and sulfur content (although
nitrogen is not expected to be present in our LMWLs). They did not offer oxygen amount
evaluation.
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4.3.2 Results
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Table 29. Elemental analysis
batches
CDSMT1
% content
Carbon
47.54
Hydrogen
3.60
Nitrogen
0.57
Sulfur
1.76

results for two batches of CDS and the average of both

Error
0.04
0.06
0.01
0.06

CDSMT2
% content
40.54
3.57
0.55
3.74

Error
0.13
0.01
0.01
0.04

Average
% content
44.04
3.58
0.56
2.75

Error
4.04
0.04
0.01
1.14

4.3.3 Discussion
The two batches of CDS had relatively similar elemental composition, with less
sulfur content in batch CDSMT1 which was synthesized in 2010 compared with CDSMT2
synthesized in 2015, possibly due to the greater amount of time to undergo desulfation
(Table 29). Carbon and hydrogen content were similar to previously published elemental
analysis data for CDS, but sulfur content was much less than expected (5.3% in literature
vs 2.75% on average for CDSMT1 and CDSMT2).
In attempt to determine what the elemental composition results may look like
structurally, an investigation of varying linkage patterns, degrees of sulfation, and extent
of decarboxylation was undertaken for polymers of 10-monomer units in length. It was
found that for CDSMT1, a polymer containing six β-O-4 linkages, three β-5 linkages, one
sulfate group, and no decarboxylation was the best match with elemental analysis results.
Water is likely bound electrostatically to CDS, and we found that inclusion of six water
molecules in the structure resulted in the best matching elemental percentages. For
CDSMT2, the best matching structure was made up of six β-O-4 linkages, three β-5
linkages, three sulfate groups, no decarboxylation, and fourteen added water molecules
(Table 30). As further support of these structures being the best representation of the
structure of CDS, computer calculated elemental composition and molecular weight of
122

CDS polymers 5, 7, 8, 10, and 13 monomer units in length containing 100% β-O-4
linkages (Table 31) and 100% β-5 linkages (Table 32) are provided for comparison.
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Table 30. Closest matching polymer structures for two batches of CDS
Monomer

Units

Structure

Chemical Info

Chemical
Formula:
C90H77Na12O56S

10
CDSMT1

Molecular
Weight:
2362.49
Elemental
Analysis:
C, 45.76
H, 3.29
Na, 11.68
O, 37.92
S, 1.36
Chemical
Formula:
C90H91Na13O70S3

10
CDSMT2

Molecular
Weight:
2687.70
Elemental
Analysis:
C, 40.22
H, 3.41
Na, 11.12
O, 41.67
S, 3.58
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Table 31. Structures and elemental analysis for CDS chains of 5, 7, 8, 10, and 13 uniformly Beta-O-4 linked monomer units
in length
Mono
-mer
Chemical Info
Structure
Units
Chemical
Formula:
C45H35Na7O28S
Molecular
Weight:
1216.74
Elemental
Analysis:
C, 44.42
H, 2.90
Na, 13.23
O, 36.82
S, 2.63
Chemical
Formula:
C63H50Na8O38S
Molecular
Weight:
1631.03
Elemental
Analysis:
C, 46.39
H, 3.09
Na, 11.28
O, 37.27
S, 1.97

5

7
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Chemical
Formula:
C72H57Na9O43S

8

10

Molecular
Weight:
1849.17
Elemental
Analysis:
C, 46.77
H, 3.11
Na, 11.19
O, 37.20
S, 1.73
Chemical
Formula:
C90H71Na11O53
S
Molecular
Weight:
2285.45
Elemental
Analysis:
C, 47.30
H, 3.13
Na, 11.07
O, 37.10
S, 1.40
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Chemical
Formula:
C117H91Na15
O71S2

13

Molecular
Weight:
3041.91
Elemental
Analysis:
C, 46.20
H, 3.02
Na, 11.34
O, 37.34
S, 2.11
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Table 32. Structures and elemental analysis for CDS chains of 5, 7, 8, 10, and 13 uniformly Beta-5 linked monomer units in
length
Mono
Chemical
-mer
Structure
Info
Units
Chemical
Formula:
C49H36
Na6
O28S

5

Molecular
Weight:
1242.80
Elemental
Analysis:
C, 47.36
H, 2.92
Na, 11.10
O, 36.05
S, 2.58
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Chemical
Formula:
C69H52
Na8
O38S

7

Molecular
Weight:
1705.12
Elemental
Analysis:
C, 48.60
H, 3.07
Na, 10.79
O, 35.66
S, 1.88
Chemical
Formula:
C79H58
Na9
O43S

8

Molecular
Weight:
1934.26
Elemental
Analysis:
C, 49.06
H, 3.02
Na, 10.70
O, 35.57
S, 1.66
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Chemical
Formula:
C99H71
Na12O56S
2

10

Molecular
Weight:
2496.60
Elemental
Analysis:
C, 47.63
H, 2.87
Na, 11.05
O, 35.89
S, 2.57
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Chemical
Formula:
C129H93
Na15O71S
2

13

Molecular
Weight:
3188.06
Elemental
Analysis:
C, 48.60
H, 2.94
Na, 10.82
O, 35.63
S, 2.01
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5. Development Status of Sulfated LMWLs
Chapter 2 describes the in vitro biological activities and in vivo pharmacodynamics
profile of the LMWL polymers, particularly for CDS which has shown promise in being
developed as a much needed and not yet available an anti-emphysema agent. To this
end, we sought to fill in the gap of information about the LMWLs, their structural
composition and physicochemical characteristics, to further their development. Little is
known about the exact structure of LMWLs, including linkage pattern, chain length,
sulfation level, and degree of decarboxylation. With so many unknowns, defining the
exact structure and physicochemical parameters is an impossible task. While previous
study of the unsulfated LMWLs was used to approximate the molecular weight of the
sulfated LMWLs, in this work we measured the sulfated LMWLs directly through SECHPLC studies.

Although LMWLs cannot be described by one exact molecular weight,

averages and percentages of chains falling in ranges of molecular weight give us an idea
of the make-up of the polymer. The figures and tables below are a summary of our best
estimates of the characteristics of the sulfated LMWLs to date.
The molecular weight distribution profile of CDS changes from bimodal when no
surfactant is used in the mobile phase of the HPLC to unimodal when Tween 80 is used
in the mobile phase (Figure 67). This indicates that some large molecular weight species,
likely an aggregate of smaller molecular weight chains, are disrupted when surfactant is
present. The unimodal profile of CDS acquired with surfactant is likely the most accurate
representation of its molecular weight distribution. The MP of CDS of ~5700 Da is ~40%
higher than the previously reported molecular weight of CDS: 3320 Da (Table 33). The
molecular weight estimate of 5700 Da is more accurate than the previous estimate
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because we measured CDS directly, whereas the previous estimate was calculated from
extrapolations of SEC-HPLC data from CD.

Proportion of Chains (%)

SEC-HPLC Profiles of CDS
100
CDS no surfactant

80

CDS 0.02% Tween

60
40
20
0
0

10000

20000

30000

Apparent Molecular Weight (Da)
Figure 67. SEC-HPLC profile of CDS represents the average molecular weight
distribution when no surfactant and 0.02% Tween 80 are used in the mobile phase
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Table 33. Summary of physicochemical properties of CDS represents the average
molecular weight distribution when no surfactant and 0.02% Tween 80 are used in the
mobile phase
Mobile phase of HPLC
Physicochemical Properties of CDS
No surfactant 0.02% Tween 80
9121 ± 910
5742 ± 512
MP (Da)
(8211 – 9311)
(5230 – 6254)
8604 ± 860
5513 ± 550
MN (Da)
(7744 – 9464)
(4963 – 6063)
12242 ± 1200
14217 ± 1400
MW (Da)
(11042 – 13442) (12817 – 15617)
Polydispersity
1.42 ± 0.2
2.58 ± 0.4
Chains < 6,000 Da
33%
65%
Chains 6,000 – 10,000 Da
33%
17%
Chains > 10,000 Da
33%
16%
Total Sulfur Content
Sulfation level per Monomeric Unit
β-O-4 linkages
β-5 linkages
Log D

2.75% ± 1.14%
0.4
~70%
~30%
0.916 ± 0.089

The summary of physicochemical properties of CDS represents the extent of what
is currently known about the character of this sulfated LMWL (Table 33).
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The SEC-HPLC profile of FDS followed a similar trend as that of CDS discussed
above (Figure 68).

Proportion of Chains (%)

Average SEC-HPLC Profiles of FDS
100

FDS no surfactant
FDS 0.02% Tween

80
60
40
20
0
0

10000

20000

30000

Apparent Molecular Weight (Da)
Figure 68. SEC-HPLC profile of FDS represents the average molecular weight distribution
when no surfactant and 0.02% Tween 80 are used in the mobile phase
The summary of physicochemical properties of FDS revealed that there is likely
one sulfate group per every two monomer units (Table 34). FDS is more sulfated than
CDS, which likely has one sulfate group every 2.5 monomer units. Like CDS, the log D of
FDS was close to 1, indicating significant hydrophobic character of the charged polymers
likely due to the contributions from their aromatic backbones.
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Table 34. Summary of physicochemical properties of FDS
Mobile phase of HPLC
Physicochemical Properties of FDS
No surfactant 0.02% Tween 80
8338 ± 871
7470 ± 828
MP (Da)
(7467 – 9155)
(6642 – 8298)
8251 ± 825
6586 ± 650
MN (Da)
(7426 – 9076)
(5936 – 7236)
11622 ± 1100
17772 ± 1700
MW (Da)
(10522 – 12722) (16072 – 19472)
Polydispersity
1.41 ± 0.2
2.37 ± 0.4
Chains < 6,000 Da
41%
51%
Chains 6,000 – 10,000 Da
31%
11%
Chains > 10,000 Da
28%
38%
Sulfation level per Monomeric Unit
Log D

0.5
0.97 ± 0.09

The SEC-HPLC profile of SDS followed a similar trend as the other sulfated

Proportion of Chains (%)

LMWLs (Figure 69).

SEC-HPLC Profiles of SDS

100

SDS no surfactant

80

SDS 0.02% Tween
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Apparent Molecular Weight (Da)

30000

Figure 69. SEC-HPLC profile of SDS represents the average molecular weight distribution
when no surfactant and 0.02% Tween 80 are used in the mobile phase
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Less of the physicochemical properties of SDS could be determined than the other
sulfated LMWLs due to anomalous results with its unsulfated precursor SD (Table 35).
Table 35. Summary of physicochemical properties of SDS
Mobile phase of HPLC
Physicochemical Properties of SDS
No surfactant 0.02% Tween 80
7765 ± 228
4354 ± 162
MP (Da)
(7537 – 7993)
(4192 – 4516)
6827 ± 680
3728 ± 370
MN (Da)
(6147 – 7507)
(3358 – 4098)
8809 ± 880
12527 ± 1200
MW (Da)
(7929 – 9689) (11327 – 13727)
Polydispersity
1.29 ± 0.2
3.36 ± 0.4
Chains < 6,000 Da
44%
85%
Chains 6,000 – 10,000 Da
45%
10%
Chains > 10,000 Da
11%
5%
Log D

1.11 ± 0.11
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6. The Effect of Lipids on Blood Coagulation
6.1

Introduction

Clinical evidence supports the idea that lipids and fatty acids effect blood
coagulation (Table 37).89-6 Patients with spontaneous venous thromboembolism (VTE)
have higher prevalence of atherosclerosis and higher triglyceride levels. 89 High-density
lipoprotein (HDL) is inversely and consistently correlated with VTE as well. 90 Dyslipidemia
is associated with hypercoagulability, endothelial dysfunction, and increased platelet
aggregation.89 Atherosclerosis is associated with activation of both platelets and blood
and an increase in fibrin turnover, which can lead to thrombotic complications.91 Statins,
a drug class that decreases the liver’s production of cholesterol, are known to reduce the
risk of VTE. 91 VTE is linked to low HDL levels and cholesteryl ester transfer protein
(CETP) modulates HDL metabolism.90
Clotting factors are known to associate with lipids at variable affinities and their
binding modifies the activity of most clotting factors.92 Triglycerides and oxidized lowdensity lipoprotein (LDL) accelerate activation of prothrombin, factor X, and factor VII.92
Phosphatidylethanolamine, cardiolipin, neutral glycosphingolipds, and HDL enhance
inactivation of factor Va by activated protein C.92 It has been shown that purified
lipoproteins activate factor VII by factor Xa in vitro.92 Glucosylceramide is known to cause
dose-dependent prolongation of prothrombin time in the presence of APC:protein S
complex.93 Sphingosine and sphinganine down-regulate thrombin generation in the
presence of factor Va, sphingosine and its analogs inhibit activation of prothrombin, and
sphingosine dose dependently prolongs factor Xa dependent clotting times.94 Thrombin
generation

is

also

inhibited

by

glucosylsphingosine,

lysosphingomyelin,

phytosphingosine, and primary alkylamines with more than10 carbons.94 It has also been
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established that a positively charged primary amino moiety and chain length of eight or
more

carbons

are

necessary

for

anticoagulant

activity. 94

Furthermore,

free

phosphatidylserine has been found to have an effect on prothrombin activation regardless
of membrane association.95 Based on these literature findings, we seek to understand
this association at a molecular level by studying the effect of lipids (and amino acids) on
the clotting time of human plasma.
Table 36. Structures of lipids chosen for clotting assay tests.
Lipid/AA involved
Effect on coagulation
HDL cholesterol
HDL was lower in VTE patients
Triglycerides
atherosclerosis
HDL
Atherosclerosis
High D-Dimer levels
Triglycerides
Oxidized LDL
Phosphatidylethanolamine,
cardiolipin, neutral
glycosphingolipds, and
HDL
Purified lipoproteins
Glucosylceramide
sphingosine, sphinganine,
and stearylamine

Sphingosine, sphinganine,
glucosylsphingosine,
lysosphingomyelin,
phytosphingosine, primary
alkylamines with more
than10 carbons

VTE pts have higher trig/atherosclerosis89
HDL inversely and consistently correlated with VTE90
Activates platelets
Increases fibrin turnover91
Increased risk of VTE91
Accelerate activation of of prothrombin, fX, and fVII92
Enhance inactivation of fVa by activated protein C92

activate factor VII by factor Xa92
Prolongs PT in the presence of APC:protein S
complex93
Inhibit prothrombin activation
Anticoagulant property of Sphingosine and related
compounds requires a hydrophobic side chain of more
than 10 carbons as well as a positive charge94
Inhibit thrombin generation
Acylation of the amino group ablated anticoagulant
activities94
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6.2

Clotting Assays Methods

Activated partial thromboplastin time (APTT) measures intrinsic coagulation factors
(VIII, IX, XI, XII, and prekallikrein) and prothrombin time (PT) measures extrinsic factors
(I (fibrinogen), II (prothrombin), V, VII, and X). Various lipids and amino acids were tested
over a range of concentrations for effect on clotting time with a fibrometer and human
plasma. The assay works by causing recalcification of plasma in the presence of tissue
factor which activates factor Xa, which then activates prothrombin to thrombin, which
converts fibrinogen to fibrin, forming an insoluble clot. The clot creates resistance that is
detected by the needle of the fibrometer, the instrument stops, and time is recorded and
compared to baseline (no lipid or amino acid added).

Table 37. Literature findings of lipid and amino acid (AA) effects on blood coagulation
Lipids
Decanoic Acid 10:0
Linoleic Acid 18:2 (cis, cis)
Methyl Linoleate 18+1:2 (cis, cis)
Stearic Acid 18:0
Eladic Acid 18:1 (trans)
Oleic Acid 18:1

140

Methyl Oleate 18+1:1 (cis)
Arachidonic Acid 20:4 (all cis)
Ethyl Arachidonate 20+2:4 (all cis)

Lipids tested included decanoic acid, linoleic acid, methyl linoleate, oleic acid,
methyl oleate, stearic acid, elaidic acid, arachidonic acid, and ethyl arachidonate (Table
36). Amino acids tested included serine, aspartic acid, lysine, alanine, glycine, and
arginine. Lipids that were not in liquid form at room temperature were dissolved in
50mg/mL bovine serum albumin (BSA) in water, 50% glycerol in water, dimethyl sulfoxide
(DMSO), and/or human blood plasma. Time taken by the plasma to clot was recorded at
baseline and after the addition of lipids and amino acids, with the resultant concentrations
of the lipid/amino acid in the assay from 0 to 20 mM. Activation time for the APTT test for
the amino acids was 3 minutes and 5 minutes for the fatty acids.
A variety of chain lengths from 10-20 carbons were chosen to be tested as part of
the lipid library to look for an effect of increasing length on clotting (Table 36). Varying
degrees and types of unsaturation (one vs two vs four double bonds; cis vs trans) were
included among lipids of similar chain length for comparison. Finally, both carboxylic acid
(negatively charged at physiological pH) and methylated/ethylated forms (no charge)
were included to determine if anionic charge effects activity of the lipid on clotting
differently than neutral charge.
APTT and PT results are reported as “2x APTT” values and “2x PT” values that
indicate the concentration of lipid/amino acid necessary to increase the clotting time two
times over the baseline (when no lipid/amino acid was added) PT or APTT clotting time.
A lower “2x” value means a lower concentration of the lipid or amino acid was needed to
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increase the baseline clotting time by 100%, therefore indicating a more potent
anticoagulation activity.
6.3 Clotting Assay Results
The majority of lipids and amino acids studied were found to have no significant
effect on the basal clotting profile of normal human plasma in both APTT and PT tests,
except for arachidonic acid, decanoic acid, linoleic acid, and oleic acid, which
demonstrated a concentration dependent increase in APTT and PT. Decanoic acid and
arachidonic acid increased clotting time for both APTT and PT in a concentration
dependent fashion more efficiently than the other lipids. Linoleic acid and oleic acid also
showed an increase in clotting time at comparatively higher concentrations, however the
ester forms (methyl linoleate, methyl oleate, and ethyl arachidonate) did not affect clotting
time. The positively charged amino acids lysine and arginine increased clotting time for
both APTT and PT in a concentration dependent fashion more efficiently than the other
amino acids. When plasma was used as the solvent results of the assay were more
reproducible than with the other solvents.
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6.3.1 APTT Lipids

APTT Lipids

Oleic Acid
Methyl Oleate

114

Clotting Time (seconds)

Linoleic Acid
94

Methyl Linoleate
74

Arachidonic Acid

54

Ethyl
Arachidonate
Decanoic Acid

34

Elaidic Acid

14
-0.005

0.005

0.015

0.025

0.035

0.045

Molar Concentration

Figure 70. APTT results of lipids
While many of the lipids tested did not significantly affect the APTT, arachidonic
acid and decanoic acid increased the APTT in a dose dependent fashion (Figure 70).
Decanoic acid had the most potent anticoagulant effect with a 2x APTT value of 9.7 mM,
followed by arachidonic acid at 25.6 mM and oleic acid at 31 mM (Table 38).
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Table 38. 2x APTT values for lipids representing the concentration of amino acid
needed to increase the APTT 100% over baseline
Lipid
2x APTT (mM)
Arachidonic Acid

25.6

±

2.5

Decanoic Acid

9.7

±

1

Ethyl Arachidonate

49.2

±

4.9

Elaidic Acid

206

± 20.6

Linoleic Acid

43.4

±

Methyl Linoleate

4.3

466.5 ± 46.7

Oleic Acid

31

Methyl Oleate

±

9.3

239.3 ± 23.9

6.3.2 APTT Amino Acids

APTT Amino Acids
Serine BSA

239

Serine 50%Gly

Clotting Time (seconds)

214
189

Lysine in Plasma

164

1.94M Lysine BSA

139

Lysine 50%Gly

114

Alanine BSA

89

Glycine BSA

64

Aspartic Acid H2O

39

Arginine in Plasma

14
0

0.01

0.02

0.03

Molar Concentration

Figure 71. APTT results of amino acids
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0.04

0.05

Most amino acids did not significantly affect the APTT, but arginine and lysine
increased the APTT in a dose dependent fashion (Figure 71). Arginine had the most
potent anticoagulant effect with a 2x APTT value of 4.5 mM, followed by lysine with 11.9
mM and aspartic acid with 14.7mM (Table 39).

Table 39. 2x APTT values of amino acids representing the concentration of amino acid
needed to increase the APTT 100% over baseline
Amino Acid

2x APTT (mM)

Alanine

234

±

23

Arginine

4.5

±

0.5

Aspartic Acid 14.7

±

1.4

Glycine

250

±

25

Lysine

11.9

±

1.3

Serine

71.1

±

17.5
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6.3.3 PT Lipids

Clotting Time (seconds)

PT Lipids

Oleic Acid

29

Methyl Oleate

27

Linoleic Acid

25

Methyl Linoleate

23

Ethyl Arachidonate

21

Arachidonic Acid

19

Decanoic Acid

17

Elaidic Acid

15
13
0

0.02

0.04

0.06

0.08

0.1

Molar Concentration

Figure 72. PT results of lipids
Most of the lipids did not significantly affect the PT, but once again arachidonic and
decanoic acid increased the PT in a dose dependent manner (Figure 72). Decanoic acid
had the most potent anticoagulant effect with a 2x PT value of 41.1 mM, followed by
arachidonic acid at 63 mM (Table 40).
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Table 40. 2x PT values for lipids representing the concentration of amino acid needed
to increase the APTT 100% over baseline. (NA = not applicable; the lipid does not
increase the APTT even at the highest concentrations tested)
Lipid
2x PT (mM)
Arachidonic Acid

63

±

6.3

Decanoic Acid

41.1

±

4.1

Ethyl Arachidonate 179.4 ±

18

Elaidic Acid

277.8 ± 27.8

Linoleic Acid

157

±

15

Methyl Linoleate

NA

Oleic Acid

266.3 ± 26.6

Methyl Oleate

NA

6.3.4 PT Amino Acids

PT Amino Acids

120

Serine
1.67M Lysine

100

1.94M Lysine

Clotting Time (seconds)

110

90

Alanine
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Glycine

70

Asapartic Acid

60

arginine

50

Lysine in Plasma

40
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0

0.01

0.02

0.03

0.04

0.05

0.06

Molar Concentration

Figure 73. PT results of amino acids
Most of the amino acids tested did not signifcantly affect the PT, but once again
lysine and arginine increased the PT in a dose dependent manner (Figure 73). Arginine
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had the most potent anticoagulant effect with a 2x PT of 9.1 mM, followed by lysine at
18.6mM (Table 41).
Table 41.2x PT values for amino acids representing the concentration of amino acid
needed to increase the APTT 100% over baseline. (NA = not applicable; the lipid does
not increase the APTT even at the highest concentrations tested)
Amino Acid
2x PT (mM)
Alanine

NA

Arginine

9.1

±

1

Aspartic Acid

65.1

±

6.5

Glycine

227.3 ± 22.7

Lysine

18.6

Serine

106.8 ± 10.7

±

1.9

6.4 Conclusions
It has been shown that increased triglyceride levels, atherosclerosis, and
dyslipidemia are associated with thrombotic complications, but the causal mechanism of
this connection is still being studied.1-6 We seek to develop a method using activated
partial thromboplastin time (APTT) and prothrombin time (PT) tests to investigate the
effect fatty acids have on clotting time of human plasma. Various lipids and amino acids
were tested over a range of concentrations for effect on clotting time with a fibrometer to
determine activated partial thromboplastin time (APTT) and prothrombin time (PT).
The majority of lipids and amino acids studied were found to have no significant
effect on the basal clotting profile of normal human plasma in both APTT and PT tests,
except for arachidonic acid, decanoic acid, linoleic acid, oleic acid, lysine, and arginine
which demonstrated a concentration dependent increase in APTT and PT. Decanoic acid
and arachidonic acid increased clotting time for both APTT and PT in a concentration
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dependent fashion more efficiently than the other lipids. Linoleic acid and oleic acid also
showed an increase in clotting time at comparatively higher concentrations than the other
lipids, however the ester forms (methyl linoleate, methyl oleate, and ethyl arachidonate)
did not affect clotting time.
Comparison of results of the fatty acids versus the ester forms suggests the acid
functional group may be responsible in some way for the molecules effect on clotting.
Lysine and arginine, which are usually protonated at physiological pH, having a more
pronounced effect on increasing clotting times compared to the other amino acids points
towards the positive amino moiety as potentially being responsible for the effect. There is
a clear in vitro effect of lipids on clotting time and more work is needed to determine which
lipids effect the clotting cascade and in what way. Also, these results with simple fatty
acids and amino acids suggest that complex lipids should be screened for their anti- and
pro-coagulant properties.
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Appendix 1

CDS
Table 42. SEC-HPLC chromatograms of batch CDSMT1 acquired with no surfactant and
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials
for each mobile phase, grouped by mobile phase; Absorbance units: mAU)

CDSMT1
Without Surfactant

0.01% Tween 80

Abs (mAU)

30000
25000

CDS MT1 1

20000

CDS MT1 2

15000

CDS MT1 3

10000
5000
0
-5000
10

0.02% Tween 80
CDS MT1 1

20000

CDS MT1 2

15000

CDS MT1 3

10000
5000

Abs (mAU)

Absorbance (mAU)

25000

0
5

7

9

16

0.05% Tween 80

30000

-5000

12
14
Elution Volume (mL)

11

16000
14000
12000
10000
8000
6000
4000
2000
0
-2000

CDS MT1 1
CDS MT1 2
CDS MT1 3

10

Elution Volume (mL)

12

14

16

Elution Volume (mL)
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18

Table 43. SEC-HPLC chromatograms of batch CDSMT2 acquired with no surfactant and
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials
for each mobile phase, grouped by mobile phase; Absorbance units: mAU)

CDSMT2
Without Surfactant

0.01% Tween 80
10000

20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0

8000
6000

CDS MT2 2

4000

CDS MT2 3

2000

Abs

Abs

CDS MT2 1

CDS MT2 1
CDS MT2 2
CDS MT2 3

0

-2000
-4000
5

10

7
9
Elution Volume (mL)

0.02% Tween 80

0.05% Tween 80
12000

12000

CDS MT2 1

10000

10000

CDS MT2 2

8000

8000

CDS MT2 3

6000

Abs

Absorbance (mAU)

14000

6000

CDS MT2 1
CDS MT2 2
CDS MT2 3

4000

4000

2000

2000

0
-2000

0
-2000

12
14
16
Elution Volume (mL)

5

7

9

11

10

Elution Volume (mL)
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12
14
16
Elution Volume (mL)

18

Table 44. SEC-HPLC chromatograms of batch CDSBH acquired with no surfactant and
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials
for each mobile phase, grouped by mobile phase; Absorbance units: mAU)

CDSBH
Without Surfactant

0.01% Tween 80
25000

Abs

CDS BH 1
CDS BH 2
CDS BH 3

CDS BH 1

20000

CDS BH 2

15000

CDS BH 3

Abs

20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0

10000
5000
0
-5000

5

11

10

13
15
Elution Volume (mL)

Elution Volume (mL)

0.02% Tween 80

0.05% Tween 80
16000

25000

14000

20000

CDS BH 1

12000

CDS BH 1

CDS BH 2

10000

CDS BH 2

CDS BH 3

15000

Abs

Absorbance (mAU)

30000

8000

CDS BH 3

6000
4000

10000

2000

5000

0
-2000

0
5

11

7
9
11
Elution Volume (mL)
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13
15
17
Elution Volume (mL)

FDS
Table 45. SEC-HPLC chromatograms of batch FDSMT acquired with no surfactant and
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials
for each mobile phase, grouped by mobile phase; Absorbance units: mAU)

FDSMT
7000
6000
5000
4000
3000
2000
1000
0
-1000

0.01% Tween 80
FDS MT 1
FDS MT 2
FDS MT 3

9000

FDS MT 1
FDS MT 2

7000

FDS MT 3

5000
3000

Abs

Abs

Without Surfactant

1000

-1000
-3000

5

10.5

7
9
Elution Volume (mL)

0.02% Tween 80
12000

FDS MT 1

10000

15000

FDS MT 1

8000

FDS MT 2

6000

FDS MT 3

10000

Abs

Absorbance (mAU)

25000
20000

16.5

0.05% Tween 80

30000

FDS MT 2
FDS MT 3

4000
2000
0

5000

-2000

0
-5000

12.5
14.5
Elution Volume (mL)

5

10.5

10
Elution Volume (mL)
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12.5
14.5
Elution Volume (mL)

16.5

Table 46. SEC-HPLC chromatograms of batch FDSJT acquired with no surfactant and
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials
for each mobile phase and one additional trial with 0.02% Tween 80, grouped by mobile
phase; Absorbance units: mAU)

FDSJT
Without Surfactant

0.01% Tween 80
5000

3500
FDS JT 1
FDS JT 2
FDS JT 3

3000
2500

4000
3000

Abs

Abs

2000

FDS JT 1
FDS JT 2
FDS JT 3

1500

2000

1000

1000

500

0

0
-500

-1000
5

7
9
Elution Volume (mL)

11

18000
16000
14000
12000
10000
8000
6000
4000
2000
0
-2000 5

17

0.05% Tween 80
5000

FDS JT 1
FDS JT 2
FDS JT 3
FDS JT 4

Abs

Absorbance (mAU)

0.02% Tween 80

13
15
Elution Volume (mL)

FDS JT 1

4000

FDS JT 2

3000

FDS JT 3

2000
1000
0

7

9

-1000
11

Elution Volume (mL)
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13
15
Elution Volume (mL)

17

Table 47.SEC-HPLC chromatograms of batch FDSBH acquired with no surfactant and
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials
for each mobile phase, grouped by mobile phase; Absorbance units: mAU)

FDSBH
Without Surfactant

0.01% Tween 80

15000

20000

13000

9000

FDS BH 2
FDS BH 3

7000

FDS BH 1

15000

FDS BH 2
FDS BH 3

10000

5000

Abs

FDS BH 1

Abs

11000

5000

3000
0

1000
-1000
4

6
8
Elution Volume (mL)

-5000

10

11

0.02% Tween 80

0.05% Tween 80
12000

16000
14000
FDS BH 1
FDS BH 2

10000

10000

FDS BH 2

8000

FDS BH 3

6000

FDS BH 3

8000
6000

4000

4000

2000

2000

0

0
-2000

5

FDS BH 1

Abs

Absorbance (mAU)

12000

13
15
Elution Volume (mL)

-2000

7
9
11
Elution Volume (mL)

11

160

13
15
Elution Volume (mL)

Appendix 2

50000

SDS

Unsulfated DHPs

SDS Reproducibility

CD Reproducibility

SDS 1

40000

CD2

30000

SDS 2

30000

CD1

CD3

20000

SDS 3

20000

Abs

10000

Abs

10000
0

0

-10000

-10000
-20000

-20000

-30000
5

6

7 Volume8 (mL)
Elution

9

10

-30000
5

Standards

Heparin Reproducibility

FD Reproducibility

40000

60000

Abs

40000

30000

FD1

HEP 1

20000

FD2

HEP 2

10000

FD3

Abs

80000

HEP 3

20000

7 Volume (mL) 9
Elution

0
-10000

0

-20000

-20000

-30000
5

6

7

8

9

5

10

7

Elution Volume (mL)

Elution Volume (mL)

Enoxaparin Reproducibility

500000

40000

400000

30000
ENOX 1

300000

ENOX 2

200000

ENOX 3

100000

SD Reproducibility

SD1
SD2
SD3

20000

Abs

Abs

9

10000
0

-10000

0

-20000

-100000
5

6

7

8

9

10

Elution Volume (mL)

-30000
5

6

7

8

Elution Volume (mL)

9

10

Figure 74. SEC-HPLC Chromatograms of SDS, unsulfated DHPs, and controls with
0.02% Triton X-100 in the mobile phase
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